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1. INTRODUCTION 
 
 
 
 
 
 
1.01 - CD40 PLAYS A KEY ROLE IN THE IMMUNE SYSTEM 
 
The immune system is a sophisticated organization of molecules, cells 
and tissues devoted to defend the host against infection.  It can act through 
innate immunity, which serves as a first line of defence but lacks the ability to 
recognize certain pathogens and to provide the specific protective immunity 
that prevents reinfection, and  through a daptive immunity, based on clonal 
selection from a repertoire of lymphocytes bearing highly diverse antigen-
specific receptors that enable the immune system to recognize any foreign 
antigen. Host defense requires many different recognition systems and effector 
mechanisms to seek out and destroy the wide variety of pathogens in their 
various habitats within the body and at its surface. 
Cytokines are small proteins that play a central role in the regulation of 
many aspects of both innate and adaptive immunity, including cell maturation, 
proliferation, recruitment at the site of infection and activation of the effector 
functions; they also control the  development and organization of peripheral 
lymphoid tissues. They are produced by various cells in the body, usually in 
response to an activating stimulus, and induce responses through binding to 
specific receptors. They can act in an autocrine manner, affecting the behavior 
of the cell that releases the cytokine, or in a paracrine manner, affecting the 
behavior of adjacent cells. Some cytokines can act in an endocrine manner, 2 
affecting the behavior of distant cells, although this depends on their ability to 
enter the circulation and on their half-life. One of the major structural families 
of cytokines, the tumor necrosis factor (TNF) family, are trimeric proteins that 
are often associated with the cell surface. They all bind members of the tumor 
necrosis factor receptor (TNFR) superfamily, a group of integral membrane 
glycoproteins that trigger multiple signal transduction pathways with functions 
in both innate and adaptive immunity [1]. 
CD40 is a member of the TNFR superfamily and was first identified in 
1984 on the surface of B lymphocytes [2]. Therefore, research on CD40 was 
initially focused around the regulation of humoral immune responses. CD40 
was identified as a molecule expressed during all stages of B cell development 
and differentiation, whereas its ligand, CD40L (CD154), was mainly expressed 
on activated CD4
+ T cells. The pivotal role of  CD40-CD40L in T cell-
dependent B cell responses was proven by the finding that individuals with 
mutations  in the gene encoding CD40L  suffered from  a severe immune 
deficiency, the X -linked  hyper-IgM  syndrome ( XHIGM or HIGM-1)  [3-7]. 
CD40-CD40L interactions  were found essential to elicit a specific, adaptive 
humoral immune response from B cells through immunoglobulin (Ig) isotype 
switching and affinity maturation, and to promote germinal center formation 
and memory B cell development [8]. Similar deficiencies in mounting immune 
responses were observed in genetically modified mice with  inactivation of 
either the CD40 or CD40L gene [9-10].  After t his breakthrough finding, 
research on CD40-CD40L has expanded in various directions. It was found that 
CD40 expression was much broader than initially thought, encompassing B 
cells, basophils, eosinophils, monocytes, dendritic cells (DC), and even non-
hematopoietic cells such as  endothelial cells,  keratinocytes, smooth muscle 
cells, eptithelial cells and fibroblasts  [8, 11].  In addition,  CD40L, though 
mainly expressed in mature CD4
+  T cells, was also found on  basophils, 
eosinophils, monocytes, macrophages, dendritic cells, NK cells, B  
lymphocytes, platelets, mast cells, endothelial cells, smooth muscle cells and 3 
epithelial cells  [11].  A common feature of all these  cells is that CD40L 
expression is non-constitutive, but can be rapidly induced upon activation. 
 
 
 
1.02 - CD40 GENE AND PROTEIN STRUCTURE 
 
A cDNA encoding human CD40 was isolated by expression  cloning 
from a library of the Burkitt lymphoma Raji  [12].  The murine cDNA was 
cloned from lipopolysaccharide (LPS) + Interleukin-4 (IL-4) stimulated murine 
B cells by cross-hybridization with the human cDNA probe [13]. Southern blot 
analysis demonstrated that the mouse CD40 gene is a single copy gene located 
on the distal region of chromosome 2, which is syntenic to human chromosome 
20q11-q13 [14]. Accordingly, the human CD40 gene, TNFRSF5, was mapped 
to chromosome 20 by using human-rodent somatic cell hybrids and to 20q12-
20q13.2 by in situ hybridization [15]. TNFRSF5 spans a 11.5 Kb region of 
genomic DNA and consists of nine exons, initially thought to be expressed as a 
single 1.5 Kb mRNA. It has been demonstrated that the murine CD40 homolog 
is expressed through alternative splicing as five different transcripts, at least 
two of which productively translated into functional proteins  [16].  In the 
present work we propose that a similar complex splicing pattern also concerns 
the human transcript. 
The 1.5 Kb mRNA encodes a protein of 277 amino acid (aa) residues 
[17]. Although its crystal structure has not yet been resolved, a model has been 
built through the use of homology modeling, mutagenesis, X-ray structures of 
TNFR, and alignment of the TNFR  family  [19].  According to this model, 
CD40 comprises a 193 aa N-terminal extracellular domain, including a 21 aa 
leader sequence (encoded by exon 1), a 22 aa transmembrane domain (entirely 
encoded by exon 7), and a 62 aa C-terminal intracellular tail (Genbank no. 
X60592). Therefore, CD40 has the structure of a typical type I transmembrane 4 
protein. Biochemical characterization suggests that the mature CD40 product is 
a phosphorylated glycoprotein that migrates in sodium dodecyl sulfate (SDS) 
polyacrylamide gel  electrophoresis as a  43-48  kDa polypeptide under both 
reducing and non-reducing conditions. It is hydrophobic, with an acidic pI of 
3.2. It  has two (Asn153, Asn180)  conserved N -linked glycosylation sites 
(Swissprot no. P25942) [8]. 
The extracellular segment of CD40 contains 20 cysteine residues which 
are thoroughly conserved in its murine and bovine homologs. Like all other 
TNF receptors, it is organized in a number of Cysteine-Rich Domains (CRD), 
in which  disulfide bonds between the Cys residues  are  critical for correct 
folding. Initially it was suggested that CD40 would form 4 CRDs of about 40 
aa each. More recently the modularity of the TNFR family has been refined, 
suggesting that every domain is  actually  built of two modules, with five 
different forms of modules being identified, each one stabilized by one or two 
disulfide bonds (Figure 1.01) [19]. 
 
The intracellular region of CD40 does not bear a close relationship to 
any other characterized molecule. Unlike most other TNFRs, it has no death 
domain; instead, it is linked to proteins called TRAFs (TNF-receptor-associated 
factors), a recently identified class of cytoplasmic messengers that interact in 
ways still largely unknown [1]. 
Fig. 1.01  -  Schematic 
representation of the CD40 
protein. The extracellular 
region of CD40 is cysteine-
rich (20 residues), as 
indicated by the horizontal 
lines. Each of the four CRDs 
can be  subdivided into two 
cysteine modules, chosen 
among the A1, A2, B1, B2 
TNFR-homology building 
blocks. Chains are connected 
by one or two cysteine 
bridges as indicated in red, 
whereas in the B1 module, 
an additional hydrogen bond 
(in blue) is formed. 
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1.03 - CD40-CD40L INTERACTIONS 
 
The structure of the TNF-like extracellular region of human CD40L 
(spanning from Gly116 to Leu261) has been resolved by X-ray crystallography 
at a resolution of 2 Å [20]. CD40L is a sandwich of two b-sheets with jelly-roll 
topology  and forms a threefold symmetric homotrimer (Brookhaven no. 
1ALY). The three-dimensional organization is similar to that described for the 
TNF-a and LTa proteins, as predicted by initial modeling studies. Combining 
these data with the proposed structural model for the CD40 receptor, it has 
been suggested that each CD40L trimer recruits three CD40 molecules on the 
surface of the target cell, and forms polar interactions based on three acidic 
residues (D84, E114, E117) on CD40 and three basic residues (K143, R203, 
R207) on CD40L. These results are mostly compatible with earlier mutagenesis 
studies identifying CD40:  E74, Y82, D84, N86, E117 and CD40L:  K143, 
Y145, Y146, R203, Q220 as  the  residues involved in CD40-CD40L 
interactions [21]. Thus the CD40L binding site has been shown to be located in 
the second and third CRD of CD40. 
The exact mechanism through which the extracellular binding of CD40L 
can elicit a response within the cytoplasm of target cells is still controversial. 
While it has been demonstrated that the stimulatory capacity of different anti-
CD40 antibodies depends on the location of the epitope on CD40 [22-23] and it 
has been suggested that binding of CD40L induces a conformational change in 
CD40 necessary for signal transduction [24-26], recent experiments in a murine 
B  cell line  with a series of deletion constructs showed  that none of the 
extracellular domains are essential for signalling via human CD40 [27]. Some 
functions, like proliferation induction, are more epitope dependent, whereas 
others,  like  rescue from apoptosis,  are  essentially epitope independent and 
probably rely simply on the cross-linking of the receptors [26]. 
By comparing the ability of soluble monomeric, dimeric and trimeric 
CD40 variants to activate transcription factors in the cytosol, it has been shown 
that the minimal requirement to induce a signal through CD40 is the formation 6 
of a receptor dimer [28], although trimerization generates a stronger signal. 
According to  Haswell  et al.  [29]  increasing valency of  the extracellularly 
applied ligand correlates with the strength of the receptor-mediated signal. 
Furthermore, it has been shown that the type and differentiation stage of the 
target cell determines not only the functional consequences of CD40 signalling 
[8], but also the level of cross-linking required to initiate a certain signalling 
pathway [25]. Accordingly, ligation via trimeric CD40L expressed on a cell 
membrane  was shown to be  essential  for the activation of some particular 
signalling pathways, such as IL-6 production in naive B cells [30].  
Several members of the TNFR superfamily spontaneously form 
oligomers on  the cell surface even in the absence of a ligand.  It  has been 
demonstrated that oligomerization of Fas, TNFR1 and TNFR2 depends on a 
conserved domain within the distal extracellular CRD [31-32]. The domain that 
mediates this interaction has been named pre-ligand assembly domain (PLAD) 
[33]. Though the PLAD seems to be physically distinct from the ligand contact 
domains, its presence is required for ligand binding [32]. It has been known for 
a  long time that CD40 purified from  resting B cells, under nonreducing 
conditions, forms dimers and multimers [17]; recently, FRET analysis 
confirmed  pre-ligand association of CD40 in the plasma  membrane  [33]. 
Although it has not yet been shown which CD40 domain is responsible for pre-
ligand assembly, homology studies suggest that PLAD is feasibly located in 
CRD1 [34], and it has been demonstrated that this domain is in fact required for 
CD40L-CD40 interaction, even though it does not contain any of the residues 
that are known to be important for ligand binding [35]. It ensues from this 
evidence that  ligand-induced signalling cannot result  from simple 
oligomerization of the receptor. It rather implies that ligand binding produces a 
change in the arrangement of the receptor that allows adapter molecules to 
bind. The advantages this pre-assembly system provides to the TNFRSF are, 
however, not fully understood.  It may  be a route to  down-regulate the 
susceptibility for ligand-induced signalling by assembly of functional receptors 
together with non-functional receptors lacking the intracellular domain [31]. As 7 
an alternative explanation, ligand binding  might promote the formation of a 
super cluster [32-34], which in turn initiates intracellular signalling events. 
Though pre-ligand association seems to be dispensable in CD40-mediated B 
cell proliferation [27], it cannot be excluded that some of the CD40 signalling 
pathways require the PLAD. 
It was recently found that CD40 depends on the microenvironment of 
lipid rafts  to function optimally  [36-38], although one group  reported 
conflicting results [39]. Lipid rafts (also  denominated membrane rafts) are 
cholesterol- and glycosphingolipid-enriched micro-domains that serve as a n 
assembly site for several receptor complexes of  central importance  in the 
immune system. For instance, the B cell receptor can be recruited in rafts after 
stimulation [40]; likewise, engagement of CD40 results in the translocation of 
CD40, as well as of its downstream signalling mediators TRAF2 and 3, to lipid 
rafts [36, 38]. Active formation of CD40L clusters is required for subsequent 
formation of CD40 clusters, which in turn is central for initiation of CD40 
signalling [41]. 
 
 
 
1.04 - INTRACELLULAR SIGNALLING EVENTS 
 
Studies on CD40 signal transduction have resulted in a complex picture 
of the different mediators and pathways  involved. Although CD40 has no 
kinase domain, CD40 ligation  activates several second messenger systems. 
Among the earliest detectable events after CD40 engagement are the activation 
of protein tyrosine kinases (PTKs, including lyn, syk, and Jak3), activation of 
phosphoinositide-3 kinase (PI-3 kinase) and phospholipase Cg2 [8]. Activation 
of protein kinase A (PKA) has been controversial, but it has been shown that 
cAMP can modulate both positive and negative CD40-induced responses [42]. 
In recent years many studies have concentrated on the  involvement of 8 
serine/threonine  kinases: stress-activated protein  kinase/c-jun amino-terminal 
kinase (JNK/SAPK), p38 MAPK, and extracellular signal-regulated mitogen-
activated  protein kinase (ERK). Contrasting results have been obtained 
regarding JNK, p38, or ERK activation [43-45]. However, general conclusions 
should be taken with care because these  studies often have used different 
cellular models. For instance activation of different B cell subsets results in 
opposite biological effects, depending on the differentiation/activation stage of 
the cells, which is probably a reflection of different  routes of signal 
transduction. 
Coupling of the CD40 receptor to different signalling pathways has been 
better understood by the identification of TRAFs. With the two-hybrid system, 
such protein-protein interactions have been demonstrated for several members 
of the TNFR family. At present six different members of the TRAF family 
have been identified. It is interesting that, although there is little cross reactivity 
between the extracellular ligands of the TNFR family, the intracellular ligands 
seem to be much more promiscuous and form a complex network of homo- and 
heterodimers. Mutagenesis of the intracellular part of CD40 has provided more 
insight into the coupling to different signal transduction pathways. 
The first member identified as a protein associated with CD40 has been 
TRAF3, a 62 kDa intracellular protein that is expressed in almost all cell types 
[46].  It contains several functional domains involved either  in signal 
transduction (RING finger domain, isoleucine zipper, zinc finger) or in protein-
protein interactions either to associate  with CD40 or to form homo-
/heterodimers. TRAF3 knockout mice show an apparently normal signaling in 
B cells, whereas T   cell activation is impaired, already pointing at the 
redundancy of the TRAF molecules [47]. 
CD40 also associates with TRAF2, a molecule that interacts  with 
TNFR2. Induction of NF-kB activation after CD40 cross-linking can in large 
part be attributed to TRAF2 signaling. Crystallography of the TRAF domain of 
TRAF2 showed a   spontaneous trimeric self-association, suggesting that the 
need for receptor trimerization might be based on the avidity for the TRAF2 9 
trimer [48]. Finally, two other TRAF proteins, TRAF5 and TRAF6, were also 
demonstrated to associate with  the CD40 receptor  [49]. Inactivation of the 
TRAF5 gene resulted in hampered B cell proliferation and up-regulation of 
various surface receptors [50]. Using wild-type CD40 and a cytoplasmic tail 
deletion mutant only containing the binding site for TRAF6 (CD40d246), it 
was demonstrated that CD40 activates ERK both by a ras-dependent pathway 
and a ras-independent pathway involving TRAF6 [51]. 
Early mutagenesis studies also suggested a critical role  for the Thr 
residue at position 254 (complete coding sequence),  implicated in TRAF3 
binding [52]. TRAF3 was cloned by screening for proteins that can interact 
with the Epstein-Barr virus (EBV) transforming gene product LMP1 (latent 
infection membrane protein-1) [53]. Physiologically, TRAF-mediated signals 
will be launched by  trimerization of surface receptors. After EBV 
transformation, it  is likely that the oligomerization of these molecules  is 
obtained by the spontaneous aggregation capacity of the LMP1 molecule. This 
indicates that EBV utilizes the CD40 signaling pathway to  activate and 
immortalize B lymphocytes. Continuous expression of LMP1 is essential for 
the proliferation of the EBV-immortalized B cells [54]. Generation of chimeric 
proteins  suggest that CD40-induced and LMP1-induced pathways are 
completely overlapping [55]. 
After early biochemical changes, these signals are translated into the 
activation of specific transcription factors that drive further gene activations. 
Cross-linking of CD40 on B cells and other cells results in activation of NF-kB 
and  NF-kB-like  transcription factors. Gel retardation assays showed the 
presence of, at least, the NF-kB family members p50, p65 (relA), and c-Rel. 
Activation of NF-kB  has been described as a  downstream effect of various 
members of the TRAF family  (TRAF2, 5, 6)  [56]. CD40-induced  NF-kB 
activation is at least partially mediated by a dramatic decrease in the half life of 
both IkB-a and IkB-b in a proteasome-dependent manner [57]. 10 
Next to NF-kB, CD40 cross-linking results in the expression/activation 
of AP1 and NF-AT transcription factors, as well as members of the Jak-STAT 
pathway, a n important route  in the signaling of  many cytokines. CD40 is 
associated with Jak3, and activation leads to phosphorylation of STAT3 [58]. 
In addition, CD40 triggering can activate the STAT6 transcription factor [59]. 
 
 
 
1.05 - BIOLOGICAL EFFECTS OF CD40 ACTIVATION ON B CELLS 
 
Extensive studies on CD40 activation of B cells have demonstrated that 
CD40 activation has major effects on many steps of the B cell natural history 
[8]. Some CD40 functions are mediated through a cross-talk with the B cell 
antigen receptor (BCR) complex [60], which consists of the membrane-bound 
immunoglobulins generated in the bone marrow during B cell maturation and 
relies on association with small transmembrane proteins, Ig-a and Ig-b, for 
intracellular signal transduction. In vitro studies have shown direct effects of 
CD40 activation  on cytokine production (IL-6, IL-10, TNF-a, LT-a), 
expression of adhesion molecules and costimulatory receptors (ICAM, CD23, 
B7.1/CD80, B7.2/CD86), and increased expression of Major 
Histocompatibility Complex (MHC) class I, MHC class II, and TAP transporter 
[61]. These molecules, which all contribute to the biological function of the B 
cells, have also provided the tools to study signal transduction pathways in 
more detail.  CD40  usually  acts in concert with either cytokines or other 
receptor-ligand interactions to guide B lymphocytes through their 
differentiation program,  and  it was shown to induce re-expression of 
telomerase activity in memory B cells, thereby contributing to an expanded 
lifespan of these cells [62].  
In vivo, most of these processes take place in  germinal centers, 
specialized microenvironments within secondary lymphoid organs. The inner 11 
region consists of rapidly proliferating  mature  B cells, which progressively 
migrate outwards and make contact with follicular dendritic cells (FDC) and 
with T cells in the outer mantle zone. Upon entering the g erminal center, B 
cells are inherently prone to die. Simultaneous cross-linking of their BCRs by 
antigens and engagement of their cell-surface CD40 by CD40L must occur in 
order to rescue B cells from apoptosis and initiate proliferation, thus forming 
the germinal center. Antigen can be provided in the form of immune complexes 
on follicular dendritic cells, or by live pathogens themselves which are carried 
to the  lymphoid tissues and multiply there until eliminated by the immune 
response, after which the germinal center decays. CD40L is provided by 
contact with activated or ‘armed’ TH2 cells, a subclass of CD4
+ T helper cells. 
Additional signals required for survival are also delivered by direct contact 
with T cells. One such signaling system, involving the TNF family member 
BLyS (B lymphocyte stimulator) on T cells and TACI (its receptor) on B cells, 
has recently been found to be essential for the maintenance of germinal centers. 
How these signals exert their effects on B cells is not completely understood. 
The combined signals from the B-cell receptor and CD40 seem to upregulate a 
protein called Bcl-XL, a relative of Bcl-2, which promotes B-cell survival. 
Armed TH2 cells activate B cells when they recognize the appropriate 
peptide:MHC class II complex on the B-cell surface. As with armed TH1 cells 
acting on macrophages, recognition of peptide:MHC class II complexes on B 
cells triggers armed helper T cells to synthesize both cellbound and secreted 
effector molecules that synergize in activating the B cell. Other than CD40L, 
secretion of the cytokine interleukin-4 (IL-4) is required to drive the resting B 
cell into the cell cycle. After several rounds of proliferation, two additional 
cytokines  secreted by helper T c ells, IL-5 and IL-6, contribute to the 
differentiation of B cells into antibody-secreting plasma cells, which provide 
Ig-mediated immune  responses against extracellular pathogens (such as 
bacteria) and many viruses, and memory B cells,  ready to respond rapidly 
during re-infection situations [1]. 12 
The primary  antibody repertoire is  generated in the bone marrow by 
means of the V(D)J recombination process that allows genomic rearrangement 
between variable (V), diversity (D), and joining (J) elements of the Ig heavy 
(CH) and light (LH) chain genes. As a result of this process, IgM and IgD 
antibodies are generated largely in an antigen-independent way. However, to 
produce potent and specific antibody responses to foreign antigens, CD40 acts 
in concert with either cytokines or other receptor-ligand interactions to shape a 
secondary antibody repertoire in peripheral lymphoid organs, by means of class 
switch recombination (CSR) and somatic hypermutation (SHM) [63]. 
CSR or isotype switching determines the effector function of antibodies 
produced by specific B cell clones via replacement of the Ig µ heavy chain (Cµ) 
with other constant (CX) heavy chains, derived from genomic elements located 
downstream from Cµ in the immunoglobulin heavy chain (IGHC) gene cluster. 
It is  a  ‘region-specific’ DNA recombination mechanism  consisting in the 
formation of a DNA double-strand break (dsb) by an as yet unidentified 
nuclease, the excision of the intervening sequences as a circularized episomal 
fragment, and  the  subsequent  DNA repair  by  nonhomologous end-joining 
(NHEJ) mechanisms, though there is some evidence that mismatch  repair 
(MMR) is also involved [64-65]. Recombination occurs within the 1-10 Kb 
switch (S) region sequences located upstream of each C X gene and tends to 
occur for t he same S region on both productive and  nonproductive alleles. 
Since  S regions  consist of repetitive elements  (either pentameric tandem 
repeats or 49 bp repeats) but lack specific signal sequences, it has been argued 
that the site of DNA  rearrangement  depends on the secondary structure 
assumed by the S region upon transcription and possibly on the formation of a 
DNA-RNA hybrid [66]. In fact, transcription of both Sµ-Cµ and the target SX-
CX  gene involved in the recombination process are required for CSR to 
commence [67]. CD40 signalling cooperates with other cytokines to trigger the 
specific I promoters located 5’ of the target CX gene and initiate synthesis and 
splicing of these so-called germline transcripts. This process is regulated by 13 
iEµ (B-cell specific transcriptional enhancer) and by control elements located 
3’ of the IgH locus [68]. 
Though CSR is initiated by CD40 engagement, the isotype specificity is 
determined by cytokines. IL-4/IL-13 induce the switch to IgE and IgG4, which 
is fine-tuned by other cytokines. IL-7 might enhance class switching to IgE and 
IgG4  [70], whereas addition of IL-10 inhibits IgE, but promotes IgG4 
production [71]. Switch to IgG1 and IgG3 is induced by IL-10, whereas IgG2 
is induced by an as yet unidentified T cell factor. Finally, the switch to IgA 
production is promoted by a combination of IL-10 plus transforming growth 
factor beta (TGFb). More recently, it has become clear that other molecular 
interactions, like interaction with DC, also might enhance the  level of Ig 
production [72], or even directly promote the switch to a specific isotype (IgA) 
[73]. In contrast, CD30, another member of the TNFR family, seems to be a 
CD40-inducible negative regulator of isotype switching [74]. 
SHM expands the antibody repertoire by introducing point mutations 
specifically  in immunoglobulin V genes of activated B cells at  an 
extraordinarily high frequency (10
-3 bases per generation, one million higher 
than during normal DNA replication) [75-76]. Interestingly, not all IgG or IgA 
undergo  SHM,  whereas some IgM are somatically mutated,  indicating  that 
CSR and SHM are independent. Similar to what was observed for CSR, CD40-
induced transcription is essential for initiating SHM. Mutations are commonly 
found within a 1.5-2 Kb region that lie 3’ to the promoter of the rearranged V 
gene, where TAA and RGYW motifs (R=G or A, Y=T or C, W=A or T) act as 
mutational hot spots. During SHM, both single- and double-strand DNA breaks 
are scattered along the DNA target sequence [77]. NHEJ is dispensable for this 
process, whereas error-prone DNA polymerases are required [76, 78]. Through 
clonal selection, SHM allows B cells to increase antibody affinity to a specific 
antigen [63]. 
For the regulation of selection of high-affinity memory B   cells, a 
complex network of interactions exists involving CD40,  Fas,  BCR, and 
cytokines. CD40 cross-linking induces Fas expression and sensitivity for Fas-14 
mediated apoptosis. However, the simultaneous triggering  of the BCR 
increases the resistance to Fas-induced apoptosis [79]. In contrast, apoptosis of 
germinal center B cells can be induced by prolonged cross-linking of the BCR, 
an effect that can be prevented by the addition of IL-4 [80]. The interplay of 
these various signaling pathways has been confirmed  in vivo  using HEL 
transgenic mice [81]. It is interesting that BCR activation also seems to block 
the induction of CD30, thereby  providing a safeguard to prevent  not only 
expansion  of non-antigen-selected B cells, but also their  unwanted isotype 
switching [74]. 
Recently, Brodeur et al. identified a 23-kD protein that bound CD40 as 
C4BP-alpha (C4BPA).  Immunohistochemical analysis showed that C4BP 
colocalized with CD40 on B cells in tonsillar germinal centers, while 
competitive binding assays showed that CD40L and C4BP bound distinct sites 
on CD40. C4BP induced proliferation, upregulation of  ICAM1 and CD86 
surface expression, and, together with IL-4, IgE synthesis in normal B cells. 
Therefore, it was proposed that C4BP is an activating ligand for CD40 and 
represents an interface between complement and B cell activation [82]. 
 
 
 
1.06 - BIOLOGICAL EFFECTS OF CD40 ACTIVATION ON OTHER CELLS 
 
The expression of CD40 on  Antigen Presenting Cells ( APCs)  like 
monocytes and DCs is now well established [83-84]. CD40 ligation results in 
an enhanced survival of these cells, in the secretion of cytokines (such as IL-1, 
IL-6, IL-8, IL-10, IL-12, TNF-a, MIP-1a) and enzymes  such as matrix 
metalloproteinase (MMP), in enhanced monocyte tumoricidal activity, and in 
the  synthesis  of nitric oxyde ( NO), which plays an important  part in 
inflammatory responses.  The interaction between CD40 and CD40L has 
important  reciprocal  consequences for both APC and T cell  function. 15 
Activation of the CD40 receptors is one of the critical signals that allows the 
full maturation of DCs into the most  powerful APCs  [85]. In turn,  CD40 
ligation considerably alters these APCs’ phenotype by upregulating  the 
expression of costimulatory molecules such as ICAM-1, LFA-3, CD80, and 
CD86, which  contribute  to the processes  of T cell priming,  proliferation, 
differentiation and effector functions, expecially increasing TH2 responses [84, 
86,  87].  CD40-CD40L interactions themselves  proved to be bidirectional: 
cross-linking of CD40L contributes to the generation of helper function and 
germinal centers [88] and considerably enhances T cell cytokine production 
[89]. There has been some controversy as to whether antigen presentation in the 
absence of CD40-CD40L interaction leads to tolerance [90]. In some models, 
like the cellular immunity against  Vesicular Stomatitis Virus (VSV), T cell 
priming seems to be independent of CD40L [91], although differences might 
exist between the induction of the cytotoxic T lymphocyte (CTL) response and 
maintenance of CTL memory [92]. 
The expression of CD40 has  now been observed on many  non-
hematopoietic cell lineages:  vascular endothelial cells and  vascular smooth 
muscle cells; keratinocytes, thymus and kidney epithelial cells; lung, dermal, 
thyroid,  gingival fibroblasts;  hepatocytes [8].  Although the expression is 
generally low in  these tissues, the  molecule is clearly up-regulated under 
various pathological conditions. Accordingly, expression can be observed in 
carcinomas  and in  many  cultured cell types including endothelial cells, 
epithelial cells, fibroblasts. Increased expression of CD40 is observed after in 
vitro activation, notably after stimulation with IL-1 or interferon-g (IFN-g). The 
functional relevance of the CD40  molecule on these cells is relatively less 
investigated.  In patients suffering from the HIGM syndrome, as well as in 
CD40 and CD40L knock-out mice, no gross abnormalities are  observed in 
these organs. However, it has been suggested that the inability to ligate CD40 
on biliary epithelial cells may contribute to a   defective defence against 
intracellular pathogens [93], whereas on some cell types, including carcinomas, 
it has been demonstrated that CD40 activation results in an induction of cell 16 
death  [94-96].  Most l ikely, CD40 expression on non-hematopoietic cells is 
relevant to inflammatory responses: in vitro CD40 cross-linking increases the 
production of cytokines, chemokines and other inflammatory mediators [97]. 
Detection of CD40 within the thymus pointed out a possible role of 
CD40-CD40L interactions in the selection of the T cell repertoire [98]. Clonal 
deletion of thymocytes bearing T cell receptors of low affinity/avidity is altered 
by the functional blockade of CD40L by anti-CD40L antibodies [99]. A useful 
consequence of this observation is the development of mouse models to test 
anti-CD40L antibodies in the treatment of autoimmunity [100]. 
Another possible therapeutic lead derives from the suggestion that 
CD40-CD40L interactions in T cell priming might inhibit tolerance induction. 
Interference with CD40 activation has been extensively investigated in murine 
models to prolong the survival of experimentally transplanted organs, including 
heart, skin, aorta and pancreatic islets allografts [101]. Although treatment with 
anti-CD40L alone prolongs survival, better results have been  obtained by 
combined treatment either with donor splenocytes or CTLA4-Ig. Simultaneous 
blocking of CD40 and CD28, a main target of APC costimulatory activity,  
resulted in long-term acceptance of skin and cardiac allografts [102]. These 
findings might open the  way to new therapeutic intervention strategies to 
prevent transplant rejection and induce long-term tolerance.  
 
 
 
1.07 - CD40-CD40L SIGNALLING DEFECTS CAUSE HYPER-IGM SYNDROMES 
 
Defects in CD40L, CD40 and some of the downstream targets of their 
signalling  cause hereditary immune  deficiencies known as Hyper-IgM 
syndromes (HIGM) due to their peculiar clinical features. 
HIGM type 1  (HIGM-1) depends on defective expression of CD40L 
and is inherited as an X-linked trait [3-7]. It accounts for 65-70% of all cases 17 
with the  HIGM phenotype.  Affected males suffer not only from recurrent 
bacterial,  but also from opportunistic infections  (e.g.,  Pneumocystis carinii 
pneumonia/PCP and watery diarrhea due to  Cryptosporidium parvum) since 
early in life. Severe  liver/biliary tract disease,  increased occurrence of 
gastrointestinal tumors, and neutropenia are additional typical hallmarks of the 
disease. Immunologic features include very low serum levels of IgG, IgE and 
IgA, with normal to increased IgM levels [103]. While primary follicles are 
present in the lymph nodes, germinal centers are characteristically absent or 
abortive. In keeping with the  defect of  CSR,  switched ( IgD
-,  CD27
+) 
circulating B cells are missing,  and in general  the number of circulating 
memory (CD27
+) B cells is markedly reduced, while the rate of SHM is only 
marginally affected [104]. In spite of the severe clinical features, which are 
suggestive of combined immune deficiency, the number and distribution of T 
cell subsets are normal, as are proliferative responses to mitogens, although in 
vitro proliferation to T -dependent antigens is  often reduced. Bone marrow 
transplantation from matched related or unrelated donors is the treatment of 
choice [105]. When none of these options are available, clinical management is 
based on regular administration of intravenous immunoglobulins (IVIG) and 
antibiotic prophylaxis. 
Defects in CD40 cause HIGM-3, a rare autosomal recessive form of 
HIGM, was first described by our group in 2001 and recognized to date in only 
five patients from  four unrelated families  [106-108].  Similar to CD40L 
deficiency, patients with CD40 mutations present during infancy with severe 
clinical symptoms, including opportunistic infections and failure to thrive, 
suggestive of combined immunodeficiency. The lack of  activation of 
monocytes and dendritic cells in the absence of CD40 may account for 
opportunistic infections in both CD40L and CD40 deficiencies. CD40-deficient 
patients were found to lack CD40 expression on the surface of B lymphocytes 
and monocytes. In vitro B cell stimulation with anti-CD40 and IL-10 failed to 
induce IgA or IgG production [106], in contrast with B cells from XHIGM 
patients who do [3-4]. Similar to XHIGM patients, CD40 deficient infants have 18 
decreased numbers of IgD
- CD27
+ memory B cells. Treatments include IVIG 
infusions every 3-4 weeks, PCP prophylaxis, and attention to nutrition. Stem 
cell transplantation is expected to be less successful [109], since it restores 
CD40 expression only for hematopoietic stem cell-derived cell lineages and not 
for other CD40-expressing cell types [110].  
Another autosomal recessive form of HIGM, HIGM-2, presents with 
mild, recurrent bacterial sinorespiratory and gastrointestinal tract infections, but 
without increased  susceptibility to opportunistic pathogens  [111-112].  It is 
caused by mutations within Activation-Induced Cytidine Deaminase (AICDA), 
the gene encoding AID, a DNA editing enzyme [113]. AID expression is 
induced by CD40 and  physiologically restrticted to germinal center B cells 
[114], where it was shown to be the only B cell specific component necessary 
and sufficient for both CSR and SHM to occur  [115].  Accordingly,  AID-
deficient patients have markedly diminished levels of IgG and IgA coupled 
with normal or elevated IgM, but unlike HIGM-1 or 3 the numbers of CD19
+ B 
cells and CD27
+ memory B cells are normal, and T cell immunity is universally 
intact [113]. A characteristic clinical finding, present in half of the patients with 
AID deficiency, is lymphoid hyperplasia due to the presence of giant germinal 
centers filled with proliferating B lymphocytes co-expressing IgM, IgD, and 
CD38. Treatment with regular infusions of IVIG is effective in reducing 
infections but does not affect lymphoid hyperplasia [116]. 
A further autosomal recessive form of HIGM is caused by defects in 
Uracyl-DNA-Glycosylase (UNG), a DNA-editing enzyme involved in CSR and 
SHM. The clinical phenotype of UNG deficiency closely resembled  HIGM-2, 
but molecular investigations in CD40 activated B cells revealed the presence of 
SHM, though the rate of transition vs tranversion was biased for certain 
residues, probably reflecting failure to remove uracil residues from DNA after 
AID deamination [117-118]. 
Recently, another form of  X-linked  HIGM characterized  by the 
association of hypogammaglobulinemia with  hypohydrotic ectodermal 
dysplasia (HIGM-ED) was identified [119-120]. This condition is caused by 19 
hypomorphic mutations of the gene encoding for NEMO-IKKg, a scaffolding 
protein for the IKKa and IKKb kinases, which regulate activation of the NF-
kB transcription factor. In HIGM-ED, engagement of CD40 or BCR is unable 
to produce  NF-kB-dependent reactions.  It is not a pure humoral deficiency 
since defects of T and natural killer (NK) cells have been also reported [121]. 
It has already been remarked that the study of HIGM-affected 
individuals was invaluable in elucidating many of the inter- and intracellular 
mechanisms involved in the immune response, like CSR and SHM. Future 
investigations of these models will certainly provide further insights on the 
delicate regulation of the immune system, as well as on new possible targets for 
the treatment of immune deficiency, autoimmunity, graft-vs-host disease and 
tumorigenesis. 
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2. MATERIALS AND METHODS 
 
 
 
 
 
 
2.01 - HUMAN TNFRSF5 GENE ANALYSIS 
 
The human CD40 gene structure was determined by alignment of the 
CD40 mRNA sequence (accession no. NM 001250) with a contig derived from 
assembled  genomic sequence data (accession no.  AL035662.60).  The nine 
exons of human CD40 gene were amplified by Polymerase Chain Reaction 
(PCR) with the following primers. Primers for exon 1: 5’-ATAGGTGGAC-
CGCGATTGGT-3’ ( fwd);  5’-TCCCAACTCCCGTCTGGT-3’ (rev).  Primers 
for exon 2: 5’-GCTGAAGAAGTTGCAACGGA-3’ (fwd); 5’-AAAGCAAAG-
GGGGACTCCA-3’ (rev). Primers for exon 3: 5’-GTTAGTGTCTGACTCAT-
GGA-3’ (fwd); 5’-AATGGCTGCATTGTCGGGA-3’ (rev). Primers for exon 
4: 5’-GGTCTGAGGAAGAAAGAGCA-3’ (fwd); 5’-CTTGGGCCCTAAGC-
TCCT-3’ (rev). Primers for  exon 5:  5’-GTGGTCCACTGTGATGGTTA-3’ 
(fwd); 5’- GAGGCCACTCTGCAGATGCT-3’ (rev). Primers for exon 6: 5’-
GTTGTGTGCTCAGTGAACCT-3’ ( fwd);  5’-ACCTTCCTAGGCTTTCT-
CCA-3’ (rev). Primers for exon 7: 5’-GTAGGGAGAAACTGCAGGT-3’ 
(fwd); 5’-CCAGATAAGAAACAGGTGGT-3’ (rev). Primers for exon 8: 5’-
GTAGGGAGAAACTGCAGGT-3’ ( fwd);  5’-GTTTTACTGCCCCATAG-
GCA- 3’ (rev). Primers for exon 9: 5’-AGGGGCTCCTCAGAGGCA-3’ (fwd); 
5’-CTCTCTGGCCAACTGCCT-3’ (rev). For exons 1, 2, 4, 5, and 9, PCR was 
performed with 2.5 units of  AmpliTaq Gold  DNA  polymerase ( Roche 21 
Molecular Systems): 1 cycle at 95°C for 10 min, and 35 cycles at 94°C for 30 s, 
at 65°C for 30 s, and at 72°C 30 s. For exons 3, 6, 7, and 8, PCR  was 
performed with 1 unit of AmpliTaq Gold DNA polymerase: 1 cycle at 94°C for 
5 min, and 35 cycles at 94°C for 30 s, at 58°C for 30 s, and at 72°C for 30 s. 
PCR products were  gel  purified by using  MultiScreen 96-well Filtration 
System  (Millipore), sequenced with  BigDye®  Terminator  v1.1  Cycle 
Sequencing Kit (Applied Biosystems), and analyzed with the ABI Prism 3730 
DNA Analyzer (Applied Biosystems) with the assistance of Sequencher 4.5 
software (Gene Codes Corporation). 
 
 
 
2.02 - CELL CULTURES 
 
B lymphoblastoid cell lines (B-LCLs) were  established  from patients 
and healthy donors via transformation of B cells with EBV by our partners at 
the Pediatric Clinic of the University of Brescia. Human Embryonic Kidney 
cells HEK-293 were kindly provided by Dr M. Vargiolu (Azienda Ospedaliera 
Universitaria di Bologna Policlinico S. Orsola-Malpighi, Dipartimento di 
Patologia Clinica, Microbiologia, Medicina Trasfusionale e Genetica Medica, 
Unità Operativa di Genetica Medica Microbiologia, Bologna, Italy). LAN-1, 
SH-SY5Y, SK-N-SH, IMR-32 and SK-N-BE neuroblastoma cell lines were a 
kind courtesy of Prof. G. Della Valle ( Università di Bologna, F acoltà di 
Scienze Matematiche, Fisiche e Naturali,  Dipartimento di Biologia 
Evoluzionistica e Sperimentale, Bologna, Italy), while AF and LAP-35 cells 
were donated by Prof. G.P. Bagnara ( Università di Bologna, Facoltà di 
Medicina e Chirurgia,  Dipartimento  Di Istologia, Embriologia  e Biologia 
Applicata, Bologna, Italy).  All cells were grown in RPMI-1640 medium 
(Cambrex)  supplemented with 10% complement-inactivated Fetal Bovine 
Serum (FBS) (Gibco), 0.3 mg/ml L -Glutamine (Euroclone, CelBio), 1 U/ml 22 
Penicillin (Euroclone, CelBio) and 0.1 mg/ml and Streptomycin (Euroclone, 
CelBio). 
 
 
 
2.03 - B CELLS SEPARATION AND STIMULATION 
 
Normal human  peripheral blood mononuclear cells (PBMC) were 
prepared from healthy donors’ buffy coat  diluted in 1 vol of PBS (10 mM 
potassium/sodium phosphate buffer with 136 mM NaCl, pH 7.4) by density 
centrifugation over Ficoll-Paque Plus (Stem Cell Technologies Incorporated). 
B lymphocytes were purified from PBMC by negative selection using MACS® 
magnetic cell sorting human B Cell Isolation Kit II (Miltenyi Biotec) as per the 
manifacturer’s specifications, and were >95% CD19
+ as determined by flow 
cytometry analysis. CD27
+ and CD27
- B cells were subsequently isolated with 
MACS® CD27 Microbeads (Miltenyi Biotec).  
Purified CD19
+, CD27
+, and CD27
- B lymphocytes were seeded at 1 x 
10
6 cells/ml in a flat-bottom 96-well plate in the presence of 1 x 10
4 irradiated 
L4.5 cells per ml. B lymphocytes were cultured  in  Iscove’s  medium 
supplemented with 50 mg/ml human transferrin, 5 mg/ml bovine insulin, 0.5% 
Bovine Serum Albumin (BSA) and 50 mM 2b-Mercaptoethanol (2b-ME), all 
from Sigma-Aldrich, and additioned with either mouse anti-human CD40 [EA-
5]  monoclonal  antibody ( MAb) ( Calbiochem) and IL-4 ( R&D Systems), or 
with SAC (Staphilococcus aureus Cowan I protein; Sigma-Aldrich) and IL-2 
(R&D Systems) for 24 hours, as described by Marconi et al. [122]. 
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2.04 - FLOW CYTOMETRY 
 
Peripheral blood lymphocytes, B-LCLs and HEK-293 cells resuspended 
in PBS at a concentration of 5 x 10
5 cells/ml were incubated at 4°C for 30 min 
with 5 ml of FITC (Fluorescein isothiocyanate)-labeled anti-human CD40 (5C3 
mAb) and  PE (Phytoerythrin)-labeled  anti-human CD19 (HIB19 mAb) 
antibodies (BD PharMingen). Pt.1 B-LCLs were also stained with anti-CD40 
[EA-5]  antibody  and a secondary  PE-conjugated anti-mouse IgG antibody 
(Caltag). After staining, the cells were washed twice with PBS, fixed with 2% 
paraformaldehyde (Sigma-Aldrich) in PBS and analyzed by FACSCalibur 
(Beckton Dickinson). 
 
 
 
2.05 - HUMAN CD40 TRANSCRIPTS ANALYSIS 
 
Analysis of CD40 transcripts in human tissues was performed on pre-
normalized, serial diluted cDNAs from a Human Rapid-Scan Gene Expression 
Panel (OriGene Technologies). For all other samples, total RNA was extracted 
from aliquots of 2 x 10
6 cells with the RNeasy Mini Kit (QIAGEN) following 
the manifacturer’s specifications, and was then subjected to Reverse 
Transcription (RT) PCR. RT reactions to obtain the cDNAs were performed on 
a GeneAmp PCR System 2700 thermal cycler (Applied Biosystems) according 
to the following protocol: addition of 500 ng Oligo-d(T) primers to 11 ml of 
RNA, incubation at 70°C for 5 min and 4°C for 1 min, addition of 1x First-
Strand Buffer, 10 mM  1,4-Dithio-DL-threitol (DTT) and 2 mM 
deoxynucleotide tri-phosphate (dNTP) Mix, incubation at 42°C for 2 min, 
addition of 1 unit Superscript II Reverse Transcriptase, incubation at 42°C for 
30 min, addition of 1 unit RNAse H, incubation at 55°C for 5 min. All reagents 
were from Invitrogen. 24 
In order to set up a screening for CD40 transcript variants, cDNA was 
amplified with four pairs of oligonucleotides ( Applera Corporation), the 
forward primer of each couple conjugated with a fluorescent dye at its 5’ end 
yielding amplicons A, B, C and D (Table 2.01). PCR was performed using 1 
unit of AmpliTaq Gold DNA polymerase and a final concentration of 1.5 mM 
MgCl2, on a  GeneAmp PCR System 2700 thermal cycler set for  initial 
denaturation at 96°C for 10 min, 25-30 cycles with denaturation at 96°C for 30 
s, annealing at 60°C for 30 s, extension at 72°C for 30 s, and a final cycle at 
72°C for 12 min. Amplicons from the same sample were pooled together at a 
volume/volume ratio of 1:1:2:3 ml for A, B, C and D respectively to correct for 
the intensity of each specific fluorescent dye and diluted in 40 ml of double-
distilled water (ddH2O). 1ml of each pool was added to 9ml of Formaldehyde 
(Sigma-Aldrich) containing 0.2ml of GeneScan 500 (-250) LIZ size standard 
(Applied Biosystems) and loaded on the ABI Prism 3730 DNA Analyzer for 
automated capillary gel electrophoresis, and the results were plotted with the 
AbiPrism GeneMapper v3.5 software (Applied Biosystems). 
 
Amplicon  Primer name  Sequence (5’￿ 3’)  Position 
       
CD40trF1,  
FAM-conjugated  GGTTCGTCTGCCTCTGCAGT  exon 1 
      A 
CD40trR1  AGCATGAGCGGTGCAGGA  exon 4 
       
CD40trF2,  
VIC-conjugated  GGTGAGTGACTGCACAGAGT  exon 3 
      B 
CD40trR2  GTCCAAGGGTGACATTTTTCGA  exon 5 
       
CD40trF3,  
NED-conjugated  CCTGTGAGAGCTGTGTCCT  exon 4 
      C 
CD40trR3  AGCACCAAGAGGATGGCA  exon 7 
       
CD40trF4,  
PET-conjugated  TTGTGCAACAGGCAGGCA  exon 6 
      D 
CD40trR4  TTGGAGCCAGGAAGATCGT  exon 9 
       
 
Table 2.01 - PCR primers used for CD40 transcript analysis. 25 
Nucleotide sequences of all the observed amplicons were validated by 
repeating the PCRs with 5’-unmodified primers and cloning the products into 
pcR2.1-TOPO vectors using the TOPO TA Cloning Kit and related protocol 
(Invitrogen). TOP10F’ strain E. coli cells (Invitrogen) were employed as a host 
for transformation (in these and in all subsequent proceedings), and colonies 
containing the recombinant plasmids were screened by PCR with the primer 
pair for the appropriate amplicon and at the same conditions described 
previously.  Nucleotide sequence analysis was  then  performed o n these 
amplification products as described for the genomic CD40 amplicons (Section 
2.01). 
To envision  the presence of full-length transcripts, cDNAs from 
neuroblastoma cell lines were also amplified with the primers employed for 
cloning wild-type CD40 mRNA ( primers 40aF and 40a1R; sequence and 
reaction conditions are detailed in Section 2.06). PCR products were separated 
on a 2% SeaKem LE Agarose gel (Cambrex) in TAE buffer (40 mM Tris, 20 
mM Acetic acid, 1 mM EDTA)  alongside a molecular weight marker 
(GeneRuler 1 Kb DNA Ladder from Fermentas) and visualized with Ethidium 
Bromide (BIO-RAD) on a Vilber Lourmat transilluminator. 
Quantitative Real-Time (QRT) PCR were performed on a BIO-RAD 
iCycler using Applied Biosystems assay-on-demand TaqMan® probes, primers 
and prortocols. 
 
 
 
2.06 - CONSTRUCTION OF RECOMBINANT VECTORS FROM CD40 TRANSCRIPT 
VARIANTS 
 
Amplicons encompassing the whole ORF of CD40 transcripts were 
generated using a forward primer overlapping the ATG start codon (40aF: 5’-
CACCGCTATGGTTCGTCTGC-3’)  and a reverse p rimer positioned 26 
downstream of the stop codon employed by the specific transcript variant we 
intended to clone (40a2R:  5’-AGGATCCCGAAGATGATGG-3’ for the 
transcript lacking exon 5, 40a1R: 5’-AACTGCCTGTTTGCCCAC-3’ for all 
others). PCRs were performed using 1 unit of Platinum pfx DNA polymerase 
(Invitrogen), which ensured high fidelity copies because of its proofreading 
activity, and the following thermal cycling conditions: 1 cycle at 94°C for 5 
min, 35 cycles at 94°C for 15 s, at 58°C for 30 s, and at 68°C for 1 min, 1 cycle 
at 68°C for 7 min. PCR products were cloned into pcR2.1-TOPO vectors using 
the TOPO TA Cloning Kit and related protocol as described in the previous 
section. Plasmid DNA of the recombinant constructs was prepared from the 
bacterial amplification host with QIAGEN Plasmid Midi Kit. Each product of 
interest was then subcloned into three expression vectors: pcDNA3 
(Invitrogen); pEGFP-N1 (Clonetech) and pFLAG-N1. The former two vectors 
were kindly provided by Dr. A. Ripalti (Azienda Ospedaliera Universitaria di 
Bologna Policlinico S. Orsola-Malpighi, Dipartimento di Patologia Clinica, 
Microbiologia, Medicina Trasfusionale e Genetica Medica, Unità Operativa di 
Microbiologia, Bologna, Italy); the latter was developed in our laboratory. 
pcDNA3-CD40 subclones were constructed by excising the product of 
interest from pcR2.1-CD40 plasmids with NotI and SpeI restriction enzymes 
and inserting it  into  pcDNA3 polylinker  at the NotI and XbaI sites. All 
restrictions were performed with endonucleases from Roche Molecular 
Systems, gel-purified with  Montage DNA Gel Extraction Kit columns 
(Millipore), and ligated overnight at 16°C at a 1:10 vector:insert molar ratio 
using 0.5 units/reaction of T4 DNA Ligase from Fermentas. 
pCD40-EGFP and pCD40-FLAG constructs were obtained by cloning 
into the NheI and SalI sites of pEGFP-N1 or pFLAG-N1 the PCR products 
generated using  pcDNA3-CD40 plasmids as templates, a common forward 
primer (40bF:  5’-ACCGTGCTAGCTATGGTTCGTCTG-3’) and reverse 
primers removing the stop codon depending on the cloned transcript (40b1R: 
5’-CTGCGGTCGACTGTCTCTCCT-3’ for wt-CD40 and del5+6-CD40, 
40b2R: 5’-TATAGTCGACCCTATTCTGGGGACCACA-3’ for del5-CD40, 27 
40b3R: 5’-CTACAGTCGACCCTCCCTGTCTCTCC-3’ for Pt.3-CD40 and 
Pt.4-CD40). PCR was performed u sing Platinum  pfx  DNA polymerase  as 
described previously in this section. 
pFLAG-N1 was developed starting from pEGFP-N1.  The sequence 
encoding EGFP was excised by restriction with SalI and NotI and substituted 
with a FLAG-encoding oligonucleotide dimer, obtained  by resuspending 
FLAG_u: 5’-TCGACTGATTACAAGGACGACGATGACAAGTAGC-3’ and 
FLAG_l:  5’-GCGGCCGCTACTTGTCATCGTCGTCCTTGTAATCAG-3’ 
(MWG-Biotech AG) in STE buffer (10mM Tris pH 8.0, 50 mM NaCl, 1 mM 
EDTA) at a concentration of 200 mM each and annealing them in a water bath 
that was gradually left to cool from 95°C to room temperature. 
All primers used in the construction of recombinant vectors were 
synthesized by Sigma-Proligo. 
 
 
 
2.07 - TRANSIENT TRANSFECTIONS AND STABLE TRANSFECTANTS 
 
All transfections were performed on 80% confluent cells using 
Lipofectamine 2000  Reagent  (Invitrogen) according to the manufacturer’s 
protocol for plasmid DNA. Stable transfectants HEK-40F and HEK-40G were 
selected for Neomycin resistance from HEK-293 cells transfected with pwt-
CD40-FLAG and pwt-CD40-EGFP, respectively, by adding 500 mg/ml G418 
(Sigma-Aldrich) to the culture medium every two days for two weeks and 
subsequent manual isolation of the resulting clones with a sterile micropipette. 
Fusion proteins originating from the pEGFP constructs were visualized 
on an Axiovert 200 inverted microscope (Zeiss) with a 20x objective. 
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2.08 - WESTERN BLOT 
 
5 x 10
6 B-LCLs, 3 x 10
6 HEK-293 or 5 x 10
6 neuroblastoma cells were 
lysed with 50 ml lysis buffer (150 mM NaCl/100 mM Tris·Cl pH 7.5, 2 mM 
EDTA, 0.5% Triton X -100, protease inhibitors) f or 30 min on ice and 
centrifuged for 10 min at 16,000 x g. Protein content of the supernatants was 
quantified with the DC Protein Assay Kit (BIO-RAD) on a DU530 UV/Vis 
Spectrophotometer (Beckman Coulter), 1 volume of SDS  gel-loading buffer 
(50mM Tris-HCl, pH 6.8 with 20% Glycerol, 2% SDS, 2% 2 b-ME, 0.02% 
Bromophenol Blue) was added to 20 mg of total protein, and the samples were 
boiled for 3 min. For B-LCLs and HEK-293 cels transfected with the FLAG 
constructs, pellets were also resuspended in 50 ml of DNAse I buffer (200 mM 
TrisH·Cl, 20 mM MgCl2), treated with 1 µl di DNAse I (Invitrogen) at room 
temperature for 1 h, and subsequently handled  like the supernatants were. 
Proteins were separated on a 12% SDS-polyacrylamide gel in a Hoefer SE 260 
electrophoretic cell ( Amersham Pharmacia Biotech) alongside a Full-Range 
Rainbow Molecular Weight Marker (GE Life Sciences), transferred to an 
Immobilon-P polyvinylidene difluoride (PVDF) membrane (Millipore) with a 
Hoefer miniVE system (Amersham Pharmacia Biotech) and probed with an 
affinity-purified rabbit polyclonal antibody (anti-FLAG from Sigma-Aldrich, 
anti-human CD40 (H-120) IgG or anti-human CD40 (C-20) IgG from Santa 
Cruz Biotechnology) following the protocol detailed in Current Protocols in 
Molecular Biology, Chapter 10 (Wiley Interscience). The blot was developed 
with the Enhanced Chemiluminescence (ECL) Western Blotting Detection 
System (Amersham Pharmacia Biotech). 
In the N-deglycosylation experiment, samples were treated for 1 h with 
Peptide-N-Glycosydase (PNGase) F (BIO-RAD) and loaded side by side to 
untreated samples for comparison. 
In the assay for presence of the CD40 variant missing exon 5, culture 
medium of del5-CD40-FLAG transfected cells was concentrated 70-fold with 
Amicon Ultra filter columns (Millipore) before Western blot analysis. 29 
2.09 - CELL FRACTIONATION 
 
Cell fractionation was carried out on HEK-293 and B -LCLs in a 
HAEREUS ultracentrifuge (courtesy of Dr P. Zucchelli, Ospedale Maggiore, 
Bologna) as described previously by Lehninger et al. [124], but purifying only 
up to the 80,000 rpm fraction. Equal quantities of total protein from all 
fractions were loaded on an SDS-PAGE gel and Western blotting was 
perfomed as detailed in Section 2.08. 
 
 
 
2.10 - IMMUNOFLUORESCENCE STAINING AND CONFOCAL MICROSCOPY 
 
In order to colocalize CD40 in specific cell compartments, we assayed 
HEK-40F stable transfectants for different markers. Cells were allowed to grow 
on sterilized coverslips for 24h, then fixed with 2% paraformaldehyde in PBS 
at RT for 30’ and blocked with 50mM NH4Cl in PBS at RT for 15’. Coverslips 
were washed with a p ermeabilization buffer, consisting of 0.2% Tween20 
(Sigma-Aldrich) in PBS, and stained by incubation at 4°C for 60 min with the 
appropriate antibodies. We used a 1:400 dilution of mouse anti-human CD40 
monoclonal antibody LOB-11 (Santa Cruz Biotechnology), a 1:100 dilution of 
rabbit anti-human Calnexin antibody [AF18] (Abcam), and a 1:1000 dilution of 
rabbit anti-human Giantin  antibody, Alexa Fluor  488 conjugated ( Abcam). 
CD40 and Calnexin staining required a second incubation with Alexa Fluor® 
568 Goat A nti-Mouse  IgG  (H+L)  (Invitrogen) and  Alexa Fluor® 488 Goat 
Anti-Rabbit IgG (H+L) (Invitrogen), respectively, both at a dilution of 1:200. 
For recycling compartment staining, Transferrin from human serum, Alexa 
Fluor® 488 conjugated (Invitrogen) was added 1:100 to the culture medium for 
60 min immediately prior to cell fixation. 30 
Staining of B-LCLs were performed following the same protocol, but 
empoying anti-CD40 (LOB-11) along with transferrin for the control sample, 
and along with rabbit polyclonal anti-PDI (Protein Disulfide Isomerase; H-160) 
IgG (Santa Cruz Biotechnology) for control and Pt.3 samples. 
Cells were visualized on a  FV300 confocal miscroscope ( Olympus). 
Images were captured using the 60X objective with the appropriate filter set. 
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3. RESULTS AND DISCUSSION 
 
 
 
 
 
 
3.01 – CHARACTERIZATION OF HIGM-3 PATIENTS 
 
In the present work we have studied four patients diagnosed with type 3 
HIGM. Patient 1 (Pt.1), born from consanguineous Italian parents, and Pt.2, 
belonging to a  multiply related  Saudi Arabian family, were  previously 
described by our group [106]. Pt.3 and Pt.4 were more recently diagnosed at 
the Pediatric Clinic of the University of Brescia [107-108]. All patients entered 
medical care at an early pediatric age because of severe or recurrent respiratory 
tract infections. They all shared normal counts of circulating B cells and a 
profound reduction of IgG and IgA serum levels, whereas IgM were present at 
normal or high levels. Systematic evaluation of differentiation markers liable to 
be aberrant in hypogammaglobulinemia patients with normal/high levels of 
IgM detected normal CD40L expression and lack of mutations in the AICDA 
gene, but flow cytometry profiles showed absence (or, in the case of Pt.4, near 
absence) of CD40 expression on the surface of peripheral blood B lymphocytes 
(Fig. 3.01). PCR amplification and nucleotide sequence analysis of each exon, 
including flanking intronic splice sites and the branch site, revealed mutations 
in the TNFRSF5 gene of all four patients (Fig. 3.02), allowing the investigators 
to assign them to the HIGM-3 group. 
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Fig. 3.01  -  Flow cytometry 
analysis of peripheral blood B 
lymphocytes stained with anti-
CD40 FITC-conjugated  IgG. 
CD40 expression on the cell 
surface is absent from Pt.1, Pt.2 
and Pt.3; there is residual 
expression in Pt.4. Panels A 
through C originally published 
by Ferrari et al., 2001 [106]; 
panels C and D are unpublished 
data from Lanzi G and Giliani S [127]. Reproduced by kind permission from the authors. 
 
Pt.1 had a single homozygous  change (A455T) at the fifth base pair 
position of exon 5, purportedly resulting in a silent mutation at codon Thr136, 
but effectively disrupting an Exonic Splicing Enhancer (ESE), a cis-element 
that promotes inclusion of specific exons  [124]  through binding of 
serine/arginine-rich splicing factors  [125].  Direct  sequence analysis  of the 
mutant cDNA product and exon-trapping experiments confirmed this mutation 
to be responsible for the systematic splicing out of the entire exon 5 during 
mRNA maturation [106]. 
Pt.2 was  homozygous for a T294C nucleotide transition in exon 3, 
resulting in a Cys to Arg substitution at residue 83, within CRD2. 
Pt.3 displayed a homozygous intronic A to T transition 2 nucleotides 
upstream of exon 4 which scrambles the correct splice site and, according to 
cDNA nucleotide sequence analysis, promotes the use of a cryptic splice 
acceptor site 6 nt downstream  [126].  The result of this variation on the 
aminoacid sequence is a deletion of Asn86 and Leu87, along with a Gly88Arg 
substitution, also within CRD2. 
Pt.4 was homozygous for the deletion of bases 174 to 176 (ATA) within 
exon 2, causing the deletion of Ile33 from the peptide sequence of CRD1. 
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Due to the patients’ condition and/or availability, in the present work we 
had no access to fresh PBMC samples, but we could resort to B-LCLs derived 
from Pt.1, Pt.2 and Pt.3 and had limited accessibility to B-LCLs derived from 
Pt.4 since they were developed by a partner research group  led by  Dr.  S. 
Giliani, at the Pediatric Clinic of the University of Brescia [127]. 
 
 
 
 
 
 
3.02 - IDENTIFICATION OF CD40 TRANSCRIPT VARIANTS IN B-LCLS 
 
Though CD40 expression is still poorly understood, its mouse ortholog 
offers clear evidence of a complex post-transcriptional regulation driven by 
alternative splicing, and some indication exists that a similar mechanism also 
occurs in man [16]. These findings, and the additional evidence that two out of 
four HIGM-3 patients owe their condition to defective splicing, prompted us to 
address the problem of identifying CD40 transcript variants by setting up a fast 
and sensible  method based on s emi-quantitative RT-PCR combined with 
capillary gel electrophoresis. 
We split the CD40 transcript into four partially overlapping amplicons 
covering all exon-exon junctions, optimizing their length for electrophoresis in 
an AB3730 automated sequence analyzer. The forward oligonucleotide of each 
Fig. 3.02 - Schematic representation of the TNFRSF5 gene. Boxes identify the various exons. The 
position of disease-causing mutations identified in patients with CD40 deficiency is indicated 
respective to the transcript (in italic) and to the peptide sequence.  34 
primer pair was conjugated with a different fluorescent dye, so that all PCR 
products from individual cDNA samples could be assayed simultaneously in a 
single capillary and discriminated by their emission wavelength. As outlined in 
Fig. 3.03, amplicon A, marked with a FAM fluorescent dye, spans exon-exon 
junctions 1 -2, 2 -3 and 3 -4; amplicon B (VIC) spans junctions 3 -4 and 4 -5; 
amplicon C (NED) spans junctions 4-5, 5-6 and 6-7; amplicon D (PET) spans 
junctions 6-7, 7-8 and 8-9. The positioning of the primers within distinct CD40 
exons and the relevant size of the intervening introns prevented contamination 
from genomic DNA derived products. 
 
 
 
 
We analyzed transcripts from B-LCLs derived from the four patients, 
along with a control B-LCL derived from a healthy donor. cDNA was prepared 
from total RNA by using an oligo-d(T) primer. To perform semi-quantitative 
RT-PCR, b-actin was used as a reference to normalize the samples and the 
number of PCR cycles was kept low. Only a small part of the reaction was 
necessary for capillary gel electrophoresis. The readout of each channel (either 
FAM, VIC, NED or PET emission) was plotted with GeneMapper software as 
a series of discrete peaks characterized by a position on the x-axis (or “size”), 
corresponding to the length of the PCR products, a nd by a n intensity (or 
Fig. 3.03 - CD40 trascript was split into four partially overlapping amplicons, each spanning a 
specific set of exon-exon junctions and marked with a different fluorescent dye. 
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“height”), approximately proportional to the relative abundance of the 
amplicons originating from any given primer pair. 
The control sample showed a main peak on each channel matching the 
expected length of the amplicon from the  full-length transcript (Fig. 3.04). 
Head-on comparison of the readouts from the various samples allowed us to 
discriminate easily transcript length variations in the patients. The plot of Pt.4 
evidenced a main peak 3 nt smaller than the control on the FAM channel only, 
consistent with the known codon deletion within exon 2. Pt.3 displayed a main 
peak 6 nt smaller than the control both on the FAM and on the VIC channel, 
which implies a deletion somewhere within exon 3 or 4, in agreement with 
previously known data.  Pt.2, of course,  showed  no size variation in any 
amplicon, since its point mutation  does not affect RNA length.  Pt.1, 
consistently with the systematic exclusion of exon 5 from the transcript, lacked 
the 292 nt peak matching full-length amplicon C on the NED channel, but 
displayed two smaller peaks which pointed out the presence of PCR products 
spanning 198 and 136 nucleotides. Their size perfectly agrees with the length 
of the amplicons that would have been obtained from a transcript in which, 
respectively, splicing out of exon 5 or of both exons 5 and 6 had occurred. 
Strikingly,  these two peaks, though weaker in intensity, were quite 
evident on the NED channel of the other samples as well, along with an even 
lower one at 230 nt on the x-axis, corresponding to the PCR product that would 
have originated from a transcript missing exon 6 only. Similarly, on the PET 
channel the main peak of every sample is flanked by two very low peaks: one 
matches the size of a variant originating from an alternative splice acceptor site 
5 nt within exon 8, while the other agrees with the use of an alternative splice 
donor site contained in intron 7, 12 nt downstream of exon 7.  The FAM 
channel of the control sample also reveals an additional faint signal falling 
short of the main peak by exactly 79 nucleotides, the precise length of exon 2. 
This peak overlaps with the main peak of the NED channel; since sometimes 
high signals on one channel are detected on other channels as well, we had to 36 
rule out this possibility by repeating the analysis and loading the PCR products 
of each primer pair on different capillaries (Fig. 3.09 B). 
 
 
 
 
 
In order to check these CD40 variants we queried either the human 
Expressed Sequence Tags (ESTs) database or the ASAP (Alternative Splicing 
Annotation Project) database (http://bioinfo.mbi.ucla.edu/ASAP/), created by 
an automated method for discovering tissue-specific regulation of alternative 
splicing through a g enome-wide analysis of the UniGene clusters of human 
ESTs. The ESTs in UniGene contain all the CD40 mRNA variants revealed by 
our method of analysis. 
Fig. 3.04 - Comparison between the plots resulting from GeneMapper analysis of CD40 transcripts 
from B-LCL samples. A) Readouts from Pt.2, Pt.3, Pt.4 and the healthy control displayed on all 
four channels mark some the different peak sizes of mutants Pt.2 and Pt.3, and the recurrence of 
splicing variants in all samples. B) Readout from Pt.1 on the NED channel higlights the absence of 
full-length transcripts and the concurrent increase in the intensity of the peaks representing splicing 
out of exon 5 and exons 5 and 6. Ctrl = control sample. 
Ctrl 
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The identity of every variant was further confirmed by inserting the PCR 
products into Topo-TA vectors and analyzing the nucleotide sequence of the 
resulting clones. Other extremely low peaks could be seen in the plots apart 
from those mentioned above, but they were sensibly discounted as either 
fluorescence artefacts or subliminal products if they both failed to occur in 
repeated experiments and were never found in any of the clones we screened. 
Though the peak intensities displayed in the readouts are related to the 
abundance of the appropriate amplicons, this technique is essentially qualitative 
and shouldn’t be used to measure differences in absolute expression levels 
between samples. In order for the assay to be at its most reliable, the highest 
peak of each plot must be kept within a certain range of values by diluting the 
sample, while normalizing the data against a reference gene is prone to yield 
off-scale readings where even small variations are concerned. Over a number 
of experiments with the B-LCLs, however, we have observed that the most 
repeatable quantitative aspect of our assay was the ratio between peak heights 
within the same sample rather than their absolute intensity value. Since 
alternative splicing ultimately means increasing certain transcript variants at the 
loss of others, all in all using peak ratios appealed to us as an appropriate 
quantitative  method to compare samples, because it reflects the actual 
biological effect of the phenomenon it describes. All these considerations 
notwithstanding, in our experiments semi-quantitative RT-PCR has always 
been performed to obtain a homogeneous array of samples, so that the optimal 
dilution of each specimen for the electrophoretic run would be in its own right 
an indication, though by no means an accurate measure, of its transcription 
level. Furthermore, it would allow this technique to be effectively combined 
with QRT-PCR if more accurate measurements were desired. 
The sensibility and efficiency of the method employed to study CD40 
transcript variants was validated on CD45, a gene that exhibits a known 
alternative splicing pattern (see Appendix A). 38 
3.03 - DETECTION OF CD40 SPLICING VARIANTS IN SUBPOPULATIONS OF 
HUMAN B LYMPHOCYTES 
 
Analysis of the B -LCLs  brought  forth  evidence of a  series of CD40 
splicing products common to all samples, even including the control.  Since 
CD40 signalling pathway is known to be constitutively activated in  EBV-
transformed cell lines [54, 128, 129], logic demanded that we should assay B 
cells from a fresh blood sample to find out whether the same pattern of PCR 
products could also be observed in normal B lymphocytes, and w hether it 
would show any variation between resting and activated cells. 
We purified three B cell subtypes, based on their surface markers: 
1)  CD19
+ cells at large, designated as total B lymphocytes; 
2)  CD19
+27
+ cells, or  memory B cells,  a part of which has already 
undergone CD40/CD40L activation in a germinal centre; 
3)  CD19
+27
- cells, representing pre-germinal centre mature B cells.  
All cells were separated using MACS
® Technology.  Applying the B cell 
Negative Isolation Kit to PBMCs obtained from a buffy coat yielded a 98% 
purified CD19
+ population by depletion of non-B cell types (we  choose to 
avoid B cell positive selection because we  had already established that 
engagement of CD19 with the anti-CD19 magnetic beads contained in the 
positive isolation kit would have caused induction of CD40 and CD19 itself, 
altering the desired experimental conditions).  
 
   
Fig. 3.05  -  Flow cytometry 
analysis with FITC-
conjugated anti-CD40 and 
PE-conjugated anti-CD19 
antibodies. 8% of total 
PBMCs separated on Ficoll-
Paque density gradient are B 
cells (left). Selection with 
MACS B cell Negative 
Isolation Kit yields a 98% 
pure population of CD19
+40
+ 
B lymphocytes (right). 39 
Mature and  memory B cells were then sorted from CD19
+ cells via 
positive selection with anti-CD27 magnetic beads. Purity of the cell fractions 
was verified through flow cytometry profiling with fluorescence-conjugated 
antibodies directed against CD40 and CD19 (Fig. 3.05). 
To further diversify those three cell populations into a wide range of 
possible activation states, we cultured them for 24 h with either anti-CD40 [E5-
A] antibody + IL-4, to activate the CD40 signalling pathway, or SAC + IL-2, to 
stimulate the BCR. We collected total RNA from a fraction of each sample 
before stimulation and 24 h afterwards. QRT-PCR for AICDA, one of the main 
targets  induced by C D40  activation,  was performed on cDNAs from  total, 
mature and memory B cells stimulated with IL-4/anti-CD40, using b-actin as 
an endogenous control. As reported in Fig. 3.06, AICDA expression levels did 
increase  after 24  h of stimulation for  all cell fractions,  confirming proper 
activation of the CD40 signalling pathway. 
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We assayed  CD40 splicing variant patterns from all  B lymphocyte 
samples with the same  house  protocol employed  for B -LCL analysis. Peak 
Fig. 3.06 - CD40 activation of B cell fractions after 24 h of stimulation with anti-CD40 IgG + IL-4, 
as determined by AICDA expression. Relative expression levels for each activated fraction were 
calculated with the DDCt method [130] baselined for the threshold cycle of the respective resting 
fraction. CD19
+ = total B cells; CD27
- = mature B cells; CD27
+ = memory B cells; aCD40/IL4 = 
anti-CD40 MAb + IL-4. 40 
sizing data confirmed the presence of all PCR products already observed in the 
control B-LCL sample. No new products were found, and neither was there any 
evidence of qualitative splicing pattern variations between the different B cell 
activation states considered. 
As for q uantitative variations, they c ould only be  described  for the 
isoforms appearing on the NED channel, since all other splicing variants were 
too close to the detection limit to support any reliable analysis. For each sample 
we recalculated the intensity of the three shorter isoforms (i.e. skipping of exon 
5, of exon 6, or of both exons 5 and 6) as a ratio of the full-length transcript. 
This effectively allowed us to directly compare the abundance of these variants 
between specimens which differ in the absoulte expression level of CD40. In 
fact, in semi-quantitative RT-PCR we detected a slight increase in overall 
CD40 expression after engagement of BCR or CD40 itself, in agreement with 
current observations on CD40 upregulation [131]. 
By plotting side by side the relative values obtained for resting B cells 
from the total, mature and memory subpopulations, we could observe that the 
proportions among the three variants and between them and the full-length 
transcript  were  quite  conserved  in the different cell types  (Fig. 3.07 A). 
Moreover, by plotting the resting fraction of each cell type next to its activated 
states we could evaluate the effects of CD40 and BCR stimulation in every 
subpopulation. Memory, CD27
+ B cells display a sensible reduction of all three 
variants (Fig. 3.07 B); since CD40 overall expression showed a tendency to 
increase in the s timulated samples, this  signifies  that  activation specifically 
bolsters the full-length variant rather than increasing the general level of CD40 
transcription. Mature, CD27
- B cells show a decrease in the variants missing 
exon 6 upon activation of the CD40 receptor, and a reduction of all three 
variants upon activation of the BCR (Fig. 3.07 C). This implies  a selective 
increase in both the full-length and the skipping of exon 5 variants in the case 
of CD40 stimulation, or in the full-length transcript alone in the case of BCR 
stimulation. 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is interesting to note that if we choose a basic sampling of B 
lymphocyte populations, namely non-treated CD19
+, CD19
+27
- and CD19
+27
+, 
and then compare peak sizing data with the information gathered on the B-LCL 
samples (Fig. 3.08), a faint signal for a PCR product matching the aberrant 
length of amplicon A in Pt. 3 can be seen on the FAM channel of most other 
samples.  Its absence from  some of the samples is likely to be an issue of 
detection limit: this PCR product was so scarce in all samples but Pt.3 that we 
overlooked it during our previous analysis of the B-LCLs alone, since it did not 
appear in any of the clones we sequenced except those obtained from Pt.3. 
With more data to draw upon, recurrence of this peak bears indication that the 
cryptic splice acceptor site systematically used in Pt.3 also works for a very 
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Fig. 3.07  -  Quantitative comparison 
between the normalized peak intensities 
of the variants missing exon 5, exon 6 
and both exons 5 and 6, expressed as a 
percentage ratio of the full-length 
transcript: in different subpopulations of 
resting B cells (A); in mature B cells 
before and after stimulation  (B); in 
memory B cells before and after 
stimulation  (C). del5+6 = skipping of 
exons 5 and 6 (136 nt peak); del5 = 
skipping of exon 5 (198 nt peak); del6 = 
skipping of exon 6 (232 nt peak); 
CD19
+ = total B cells; CD27
- = mature 
B cells; CD27
+ = memory B cells; 
aCD40/IL4 = 24 h stimulation with anti-
CD40 MAb + IL-4; SAC/IL2 = 24 h 
stimulation with SAC + IL-2. 
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limited proportion of transcripts in normal B cells, hypothetically because of 
random errors in exon recognition by the splicing machinery. 
 
 
 
 
 
 
3.04 - DETECTION OF CD40 TRANSCRIPT VARIANTS IN SEVERAL DIFFERENT 
HUMAN TISSUES 
 
While to the best of our knowledge the relevance of CD40 in HIGM-3 
syndrome only concerns its presence on B lymphocytes and antigen presenting 
cells, this receptor is also widely expressed in non-hematopoietic cells, mostly 
with a pro-inflammatory role  [8, 11]. In order to investigate the splicing 
behaviour of CD40 in a comprehensive range of cell types, we applied our 
transcript variant analysis to a panel of pre-normalized, serial diluted cDNAs 
from 24 different  human  tissues and developmental stages, commercially 
available from OriGene Technologies. Initially we tested the panel for CD40 
expression in a QRT-PCR, using b-actin as a reference housekeeping gene and 
Fig. 3.08  -  Comparison 
between the FAM 
channel peaks from 
subpopulations of resting 
B cells and from B-LCLs 
highlights the recurrence 
of a low signal matching 
the main peak of Pt.3, 
i.e. a transcript using a 
cryptic splice acceptor 
site 6 nt within exon 4. 
Peak heights are reported 
as read by GeneMapper, 
and no normalization 
was made between the 
two sample groups. 
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the expression level from PBLs as a baseline value for the DDCt calculation 
method. Relative expression levels in all other tissues, albeit detectable, were 
very low, with the exception of the brain that showed transcription levels more 
than ten times higher than PBLs (Fig. 3.09 A). This data fits in well with the 
numerous reports on the abundance of CD40 expression in the microglia [132]. 
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Fig. 3.09 - A) CD40 expression levels in a range of different human tissues/developmental stages, 
calculated with  the  DDCt method baselined for the threshold cycle of Peripheral Blood 
Lymphocytes (PBLs). B) Comparison between GeneMapper plots from muscle and control B-LCL 
samples on the FAM channel highlights the marked incidence of skipping of exon 2 in the former 
sample. C) Comparison between GeneMapper plots from brain and control B-LCL samples on the 
NED channel reveals absence of the transcripts missing exon 6 or both exons 5 and 6 in brain. 
Tissue 
samples 
Ctrl 
Ctrl 
Muscle 
Brain 
B 
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A 44 
We had to exclude uterus, prostate, skin, bone marrow and fetal tissues 
from the splicing variant analysis on account of their expression levels being so 
modest they would bring the less represented splicing variants well below the 
detection limit of our assay. It should be noted here that no indication was 
given by the supplier on tissue handling prior to RNA extraction, therefore 
most samples are likely to be contaminated by the CD40-expressing endothelial 
cells of capillary blood vessels. 
Splicing variant analysis of the gene expression panel revealed the same 
products and patterns already observed in the previous experiments, with two 
noteworthy exceptions: muscle and brain (Fig. 3.09 B and C). The muscle 
showed comparable levels of full-length amplicon A and skipping of exon 2 on 
the FAM channel. The brain, despite its general high level of CD40 expression, 
displayed no detectable variants missing exon 6 on the NED channel, either 
alone or in conjunction with exon 5. 
 
 
 
3.05 - SIX CD40 SPLICING VARIANTS ARE CONSERVED THROUGHOUT 
DIFFERENT CELL TYPES 
 
Overall, other than the canonical full-length transcript and the defective 
mRNAs from affected individuals,  combining the data from the previous 
experiments  we identified at least  six CD40 splicing variants  frequently 
recurring above the detection threshold of our assay. Their identity and the 
predicted outcome of their translation are summarized in Fig. 3.10. 
Skipping of exon 2  leads to a frameshift, generating a premature 
termination codon (PTC) at the beginning of exon 3. According to state-of-the-
art literature on mRNA regulation, the position of this PTC is very likely to 
direct the transcript toward nonsense-mediated mRNA decay  [133]. 
Furthermore, the predicted protein would be barely 1 aminoacid longer than the 45 
signal peptide, a product which makes no sense and which is far too unstable to 
be effectively translated. Either way, this variant implies a co-transcriptional or 
co-translational control of CD40 expression.  Muscle tissue could provide a 
good model to investigate this kind of regulation, since splicing out of exon 2 
appeared to occur nearly as often as its inclusion in the full-length transcript 
(Fig. 3.09 B). 
The use of an alternative 5’ splice site in intron 7 adds 12 nt to the 
canonical 5’ end of exon 7, resulting in a Lys216 to Ser mutation and in the 
insertion of 4 residues (Glu-Ser-Ser-Glu) at positions 217-220. Predicting the 
outcome of this  variation on protein stability/receptor function would prove 
difficult, since  it occurs  immediately beneath the transmembrane domain 
(entirely coded within exon 7),  but  upstream of the signal-transducing 
cytoplasmic tail of CD40. 
The use of an alternative 3’ splice site in exon 8 causes a frameshift, 
which generates a stop codon 21 nt downstream of the new exon-exon junction. 
Provided it does not undergo nonsense-mediated RNA decay, this transcript 
will translate into a protein lacking the cytoplasmic tail and therefore incapable 
of signal transduction. 
Skipping of exon 5 leads to a frameshift and to the formation of a PTC 
within exon 7. Translation would produce a protein retaining two and a half of 
the four CRDs from the extracellular portion of the receptor, but ending with a 
frameshift-generated sequence of 26 aa which bears no homology to any other 
known human protein accessible through a BLAST query. Transmembrane and 
intracellular domains are completely missing. From the information gathered, 
three hypotheses on this splicing variant can be surmised: its product could be a 
soluble, and possibly secreted, isoform of CD40 still retaining some ligand-
binding capability;  its product  could be misfolded and/or degraded; the 
transcript could be subjected to nonsense-mediated RNA decay. The two latter 
conjectures would indicate a post-translational or co-transcriptional regulation 
of CD40 expression, while the former  suggests a  product with a distinct 
biological role. 46 
Skipping of exon 6 also leads to a frameshift and to the formation of a 
PTC within exon 8. It would encode a product similar to the variant missing 
exon 5, but with a more extended CRD region fused to 38 frameshift-generated 
residues. The effective outcome of translation would also contemplate the same 
hypotheses exposed for skipping of exon 5. The presence of three CRDs 
instead of two does not necessarily mean greater protein stability, since TNFR 
superfamily members are known to have a number of CRDs ranging from one 
to six [34]. Position of the PTC near the 3’ end of exon 8, though, would make 
nonsense-mediated RNA decay unlikely for this transcript. 
Skipping of both exons 5 and 6 causes the downstream sequence to 
remain in-frame, with a deletion 156 nt encompassing the region coding for 
CRD4 and half of CRD3. Unless foiled by misfolding and degradation, this 
transcript  can  generate a protein retaining  the  whole  transmembrane and 
cytoplasmic domains, which would reasonably represent an isoform of CD40 
with  the same membrane localization but  impaired binding capability. 
Functional binding of a TNF-like ligand to a receptor with non-canonical, 
incomplete CRDs has already been described for BAFF/BR3 [134]. 
Some of these splicing variations are not mutually exclusive and could 
occur within the same transcript; when a single pair of PCR primers was used 
to amplify the entire ORF from CD40 cDNA, though, this was never observed.  
Most of the alternatively spliced variants are weakly expressed, making 
analysis of their physiological function difficult. For this reason, further efforts 
in our investigations focused on the two most abundant isoforms, namely those 
generated by skipping of exon 5 and by skipping of both exons 5 and 6. While 
cloning the PCR products from the control B-LCL to confirm their sequence, 
these two were the only variants to be found in more than 1% of the clones. We 
also took advantage of the fact that Pt.1 chiefly expresses these two specific 
variants in a wt-CD40 knockout environment, providing a good model for this 
kind of analysis. 
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3.06 - DETECTION OF THE CD40 PROTEIN 
 
  Detection of the  CD40  protein  was performed by Western Blot on 
lysates from Pt.1, Pt.2, Pt.3 and control B-LCLs, using either anti-CD40 (C-
20), a polyclonal IgG raised against the intracytoplasmatic C-terminus of the 
receptor, or anti-CD40 (H-120), recognizing the extracellular CRDs (Fig. 3.11). 
 
 
                   
 
 
The same amount of total proteins was loaded from each sample. In the 
supernatant fraction of the control lysate, containing membranes and soluble 
proteins, both antibodies revealed with similar efficiency the 45 kDa band 
characteristic of CD40. The pellet from the lysate, containing nuclei and cell 
debris, shows just a trace of CD40, probably due to contamination with the 
supernatant fraction. In the lysate from Pt.1 B-LCL only faint bands at a small 
molecular weight were detected. Since they were present in all lysates, they are 
likely to be the result of aspecific binding, but lacking a CD40 knock-out as a 
negative control we could not rule out the possibility that they could be CD40 
isoforms or degradation products. Lysates from Pt.2, Pt.3 and B-LCLs were 
positive, but for a band at a molecular weight slightly smaller (35 kDa) than the 
expected. Their aminoacid sequence variations by themselves were too small to 
Fig. 3.11 - Western blots showing B-LCL lysates probed with anti-CD40 (H-120) IgG, directed 
against the extracellular domains of CD40 (left) or with anti-CD40 (C-20) IgG, directed against the 
C-terminal, intracellular region of CD40 (right). Analysis of the pellet fraction, containing nuclei 
and cell debris, revealed only traces of the CD40 protein, hence it was discontinued unless 
otherwise noted. Anti-CD40 (H-120) IgG showed a remarkably different affinity among the CD40 
variants, whereas anti-CD40 (C-20) recognized all of them equally well. Both antibodies failed to 
reveal any of the expected CD40 products in Pt.1 lysate. s=supernatant, p=pellet 
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Ctrl  Pt.2  Pt.3 
PNGase F  -       +  -        +  -         + 
wild type 
N-deglycosylated 
account for the observed weight difference, unless they somehow hampered 
protein maturation. Indeed, anti-CD40 (H-120) IgG showed weaker recognition 
of the mutant proteins than anti-CD40 (C-20), suggesting that these sequence 
variations affected the modification of the CRDs. 
In silico prediction of post-translational modifications identified two 
putative N-glycosylation sites (centered around  Asn153 and Asn180) in the 
extracellular region.  We removed all N -linked oligosaccharides by  treating 
lysates from Pt.2, Pt.3 and control B-LCLs with PNGase F; the same test was 
eventually repeated for Pt.4 at the Pediatric Clinic of the University of Brescia 
with identical results (data withheld by the investigators). Complete N -
deglycosylation brought the molecular weigth of the mutant and wild-type 
proteins on the same level, evidencing incomplete glycosylation of the mutants 
during maturation (Fig. 3.12). This defect is probably caused by a misfolding 
of the CRDs that prevents exposure of the correct Asn residues for 
oligosaccharide modification.  Failure to undergo proper glycosylation is 
predicted to thwart protein folding even further and check its maturation at the 
Endoplasmic Reticulum (ER)/Golgi level, which would explain why the mutant 
proteins fail to be exposed on the plasma membrane. 
 
 
 
Confocal microscopy on B-LCLs derived from Pt.3 confirmed retention 
of the mutant  protein  in the  ER, as defined by staining with an anti-PDI 
antibody, while on control B-LCLs CD40 was correctly localized on the cell 
surface (Fig. 3.13). 
 
Fig. 3.12 - After 1 
hour digestion with 
PNGase F, which 
removes N -linked 
oligosaccharides, 
the protein scaffold 
assumes the same 
weigth in both the 
control and the 
patients. 50 
 
   
 
 
These observations demonstrate the importance of glycosylation in 
CD40 functional maturation. Since the N-glycosylated residues Asn153 and 
Asn180 are encoded respectively within exon 5 and exon 6, the putative CD40 
isoforms originating from transcripts lacking one or both of these exons would 
arguably undergo an inefficient maturation as well. Even if a small fraction 
managed to fold productively, it could prove difficult to detect, since it would 
probably bind anti-CD40 (H-120) IgG with low affinity, and only the in-frame 
variant would be recognized by anti-CD40 (C-20). 
 
 
 
 
Fig. 3.13 - Immunofluorescence staining of control (A) and Pt.3 (B) B-LCLs for CD40 (left panels) 
and ER (middle panels). Mutant protein from Pt.3 tends to accumulate on one side of the cell. 
Merging the channels (right panels) shows colocalization of Pt.3 mutant CD40 and the ER, while 
the wild-type protein correctly becomes localized on the plasma membrane. 
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3.07 - RECOMBINANT CONSTRUCTS AND STABLE CELL LINES EXPRESSING 
CD40 AND ITS VARIANTS ALLOW CONSIDERATIONS ON PROTEIN STABILITY 
 
In order to facilitate CD40 products recognition in W estern blot, to 
better pinpoint their localization in cells, and in general as an aid to 
understanding CD40, we cloned the most relevant variants into three different 
sets of mammalian expression vectors: pcDNA3, pEGFP-N1 and pFLAG-N1. 
All plasmids guarantee good expression levels since the heterologous gene is 
placed under the transcriptional control of the highly efficient IE-CMV 
promoter. 
We elected to clone cDNAs obtained from the  wild-type full length 
transcript (wt-CD40), from Pt.3 full-length transcript (pt3-CD40), from Pt.4 
full-length transcript (pt4-CD40), and from the wild-type transcripts missing 
exon 5 (del5-CD40) or both exons 5 and 6 (del5+6-CD40). Since in Western 
blot analysis Pt.2 beheaved exactly as Pt.3, we saw fit to delay development of 
constructs containing Pt.2 CD40 until we could gather more data on Pt.3. CD40 
transcriptional state of Pt.1 is reproduced by vectors del5-CD40 and del5+6-
CD40. 
pcDNA3 constructs were used to express unmodified gene products 
from the individual CD40 variants. 
In  pEGFP-N1 constructs the C -terminal end of the CD40-derived 
peptides was fused with the Enhanced Green Fluorescence Protein ( EGFP), 
which allows direct visualization of the heterologous products in live cells via 
fluorescence microscopy. EGFP was joined at the C -terminus of the CD40 
products because  modification of the N -terminus was predicted to interfere 
with folding. A large drawback is that EGFP takes up a large part of the 
chimeric protein, particularly where the short del5-CD40 isoform is concerned: 
the fluorescent moiety comprises 239 residues and weighs 27 kDa, whereas for 
instance wt-CD40 is only 277 aa long and weighs about 4 5 kDa in its 
glycosylated form. This may well  affect protein stability, and almost surely 
prevents TRAFs binding and signal transduction. 52 
pFLAG-N1 constructs express the CD40 variants as fusion proteins 
with a C-terminal FLAG
® epitope tag. This small octapeptide is very unlikely 
to adversely affect folding or protein stability, and allows indirect detection of 
the recombinant products with an anti-FLAG MAb. 
All vectors were used for transient expression in HEK-293 mammalian 
cells. RT-PCR confirmed that all heterologous genes were transcribed correctly 
and efficiently by the host cells. 
Expression of the EGFP-tagged variants was easily verified through 
fluorescence microscopy (Fig. 3.17). Western Blot analysis with anti-CD40 (H-
120) IgG confirmed the correct size of the EGFP-tagged products (Fig. 3.14 B), 
but failed to detect pcDNA3-based constructs del5-CD40 and del5+6-CD40 
altogether (Fig. 3.14 A). 
Western Blot analysis of the FLAG-tagged recombinant products with 
an anti-FLAG MAb revealed expression of all but the del5-CD40-FLAG 
construct (Fig. 3.14 C), and reblotting with anti-CD40 (H-120) IgG provided 
identical results. Since according to structure prediction del5-CD40 product 
should be soluble and possibly secreted, we searched for it in a serum-free 
culture medium in which HEK-293 cells transfected with del5-CD40-FLAG 
were grown for 24h. Even concentrating the medium 70-fold, though, we found 
no trace of it either with anti-FLAG MAb, or by reblotting with anti-CD40 (H-
120) IgG (data not shown). Presumably, del5-CD40 is recognized as an 
aberrant product and downregulated at the translational level, and it was only 
observed as a fusion peptide with EGFP because the EGFP moiety  itself 
granted stability to the whole protein. This consideration might also hold true 
for del5+6-CD40 and del5+6-CD40-FLAG. 
In order to gain a more robust tool for experiments dealing with protein 
analysis, we also established two stable cell lines that constitutively expressed 
wt-CD40-FLAG (designated as HEK-40F) or wt-CD40-EGFP (designated as 
HEK-40G). HEK-293 cells were used as a host because they do not express 
endogenous CD40 (Fig. 3.15 panel A), and since they were originally derived 53 
from human embryonic kidney they should carry out protein maturation in the 
correct species-specific manner. 
 
 
 
                     
 
Fig. 3.14  -  Western blots 
showing lysates from HEK-
293 cells transfected with 
the recombinant vectors: 
pcDNA3 constructs (A), 
pEGFP constructs ( B) and 
pFLAG constructs (C). A 
and B were probed with 
anti-CD40 ( H-120) IgG, 
since del5-CD40 products 
lack the correct C-terminus 
and could not possibly be 
revealed by anti-CD40 (C-
20).  Reblotting with anti-
CD40 (C-20) confirmed 
this assumption (data not 
shown). C was probed with anti-FLAG MAb, and later reprobed with anti-CD40 (H-120) (data not 
shown). s=supernatant, p=pellet, w=whole lysate, Ctrl-=transfection with appropriate empty 
vector, Mock=mock transfection (without plasmid DNA) 
 
 
 
3.08 - EXPOSURE OF THE CD40 VARIANTS ON THE PLASMA MEMBRANE  
 
We  analyzed  HEK-293 cells transfected with wt-CD40,  wt-CD40-
FLAG,  del5+6-CD40,  del5+6-CD40-FLAG  and  pt4-CD40-FLAG in a flow 
cytometer to detect cell surface exposure of the appropriate CD40 variant. 
Presence of wt-CD40 and wt-CD40-FLAG on the cell surface proved to be fair, 
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though expression level and number of positive cells were considerably lower 
compared to the control B-LCL (Fig. 3.15 panel A). del5+6-CD40, del5+6-
CD40-FLAG and pt4-CD40-FLAG all displayed poor surface expression, with 
del5+6-CD40 being barely detectable and  del5+6-CD40-FLAG showing the 
greatest CD40 exposure among the three (Fig. 3.15 panels B through E). On 
one hand, this seems to indicate that the FLAG epitope does help stabilize the 
del5+6-CD40 peptide, which is an interesting result per se since the C-terminal 
end of a TNFR family member is not supposed to influence stability of the 
whole protein to such extent. On the other hand, this proves that the CD40 
mutation of Pt.4 is leaky and does not prevent surface exposure completely. 
 
 
 
Given that cytofluorimetric analysis sucessfully detected del5+6-CD40 
on the cell surface, failure to do so in Western Blot probably depended on poor 
translation efficiency combined with suboptimal affinity of the polyclonal 
Fig. 3.15 - Flow cytometry analysis of HEK-293 transfectants with FITC-conjugated anti-CD40. 
A) Histogram plot of wt-CD40 and wt-CD40-FLAG shows surface expression levels  halfway 
between control B -LCLs and non-transfected HEK-293 cells. Non-transfected HEK-293 cells 
proved to be a good negative control because staining with either anti-CD40 or anti-IgG antibodies 
produced perfectly overlapping profiles (data not shown). B and C) Histogram plots of del5+6-
CD40 compared with del5+6-CD40-FLAG and pt4-CD40-FLAG, respectively. D and E) Density 
plots of del5+6-CD40 and del5+6-CD40-FLAG. 
A  B  C 
D  E 55 
antibodies for the variant peptides; hence the need to evaluate FLAG-tagged 
proteins and test anti-CD40 IgGs from different sources. 
Since systematic splicing-out of exon 5 makes del5+6-CD40 the only 
possible membrane isoform in Pt.1 cells, the hitherto-unexpected observation 
of del5+6-CD40 on the transfectants surface prompted us to carry out in-depth 
cytofluorimetric investigations on Pt.1 B-LCLs. Staining with anti-CD40 [E5-
A] IgG, which was raised against a different epitope than those recognized by 
the antibodies previously used in flow cytometry or Western blot, showed a 
definite signal on the surface of Pt.1 B-LCL (Fig. 3.16), marking the exposure 
of a CD40 variant. This result might have a deeper significance: according to 
product specifications, anti-CD40 [E5-A] IgG performs as an activating ligand 
for CD40 (and its efficiency has already been observed on B cells, as detailed 
in Fig. 3.06). Whatever it is the exact CD40 variant it recognizes, its binding 
could  feasibly  exert a biological effect, possibly through cross-linking and 
clustering of the CD40 isoform. High levels of the variant missing exons 5 and 
6  revealed in Pt.1 transcript analysis,  together with  structural predictions 
suggesting the retention of pre-ligand association capability,  offer strong 
indications that del5+6-CD40 might be exactly the antigen detected by the anti-
CD40 [E5-A] antibody. 
 
      
 
 
 
Fig. 3.16  -  Flow 
cytometry analysis 
of Pt.1 vs. control 
B-LCLs stained 
with an anti-CD40 
[E5-A] activating 
antibody and a 
PE-conjugated 
secondary IgG. 56 
3.09 - LOCALIZATION OF THE CD40 PROTEIN VARIANTS WITHIN CELL 
COMPARTMENTS 
 
 
 
Fig. 3.17  -  Fluorescence microscopy of live HEK-293 cells transfected with: A) pEGFP-N1 
(control vector); B) wt-CD40-EGFP; C) del5+6-CD40-EGFP; D) del5-CD40-EGFP; E) pt3-CD40-
EGFP; F) pt4-CD40-EGFP. All images were captured on an inverted microscope with a 20x 
objective, overlaying fluorescence and transmitted light in order to outline the cells. 
F  E 
D  C 
B  A 57 
Fluorescence microscopy performed on HEK-293 cells 24 h post 
transfection (p.t.) with the EGFP-tagged constructs provided us an overview on 
the behaviour of the CD40 variants in live cells (Fig. 3.17). wt-CD40-EGFP 
could be seen defining the plasma membrane even in the outstretched cell 
processes, and formed inclusion bodies in cells where expression of the 
heterologous protein was greater/more prolonged (confirmed by observation at 
later times p.t., data not shown). del5-CD40-EGFP displayed a diffuse 
cytoplasmic distribution, which in a few cases coalesced in a punctate pattern. 
del5+6-CD40-EGFP, pt3-CD40-EGFP and pt4-CD40-EGFP accumulated in a 
small number of inclusion bodies in the perikaryal area. pt4-CD40-EGFP 
showed a tendency to form more discrete granules resembling vesicular 
deposits, whereas the other two recombinant proteins sometimes spread to 
outline part of the nucleus in a manner reminiscent of cis-Golgi. 
Through ultracentrifugation we isolated different cell fractions from 
HEK-293 cells transfected with wt-CD40-FLAG or del5+6-CD40-FLAG (Fig. 
3.18 A). Both CD40 isoforms were present in the fractions corresponding to 
mytochindria/lysosomes/peroxysomes and microsomes/small vescicules, and 
were indeed more abundant in these compartments than in the cell membrane. 
The nuclear fraction of HEK-293 transfectants appeared to contain small 
amounts of CD40, particularly where del5+6-CD40-FLAG is concerned. 
Though this result would agree with the nuclear localization of CD40 proposed 
by Lin-Lee et al. [135], we never observed CD40 isoforms within the nuclei of 
B-LCLs, and neither did we find any trace of them in the nuclei of transfected 
HEK-293 cells by EGFP fluorescence or, in later experiments, indirect 
immunofluorescence. 
Surprisingly, fractionation of the control B-LCL also showed that the 
mytochindria/lysosomes/peroxysomes and  the  microsomes/small v esicles 
fractions were particularly enriched in CD40  with respect to the plasma 
membrane fraction (Fig. 3.18 B). Since plasma membrane is the site normally 
associated with CD40 function, consistent intracellular presence of the protein 58 
indicates some form of post-translational control on CD40 expression, either 
through internalization or by retention in the ER/Golgi vesicles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We performed confocal microscopy on HEK-40F to identify the exact 
intracellular compartment in which CD40 accumulates. Fluorescence staining 
with anti-CD40 (LOB-11) IgG  located  wt-CD40-FLAG  partly on the cell 
membrane, and partly in a single intracytoplasmic region near the nucleus. It 
did not colocalize with either Calnexin, an ER marker, or Giantin, a cis-Golgi 
marker  (Fig.  3.19 A  and B ).  On closer examination, t he intracytoplasmic 
accumulation of CD40 and the Golgi structures evidenced by Giantin appeared 
juxtaposed (Fig. 3.19 row C), as if CD40 was retained in a nearby intracellular 
Fig. 3.18 - Western blot with anti-CD40 (H-120) antibody after cell fractionation of HEK-293 
transfectants (A) and B-LCLs (B). Non-transfected HEK-293 cells were used as a negative control.  
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Fig. 3.19 - Confocal microscopy analysis on HEK-40F cells (A-D) and B -LCLs (E). CD40 is 
stained in red (left panels), while the green staining (middle panels) is associated with Calnexin/ER 
(A), Giantin/Golgi (B, and detail of cytoplasmic accumulation of CD40 in C), or Transferrin/ 
recycling compartment (D and E). 
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membrane compartment. In fact, by incorporation of fluorescin-conjugated 
human serum transferrin in live cells prior to fixation, we finally localized the 
CD40 intracytoplasmic fraction within the recycling compartment (Fig. 3.19 
D). Further IF analysis also confirmed the presence of CD40 in the recycling 
compartment of control B-LCLs (Fig. 3.19 E). 
 
 
 
3.10 - ANALYSIS OF CD40 SPLICING IN NEUROBLASTOMA CELL LINES 
 
  The information gathered  from the  CD40  splicing variants  assays 
highlighted the peculiarity of brain tissue as regards expression level and 
splicing pattern,  and  prompted us to extend  our analysis to  cells from the 
central nervous system. Additional spur to follow this lead came from the fact 
that Pt.1 shows signs of mental retardation, though her situation is unclear and 
environmental conditions may have played a significant part in her impairment. 
It is widely accepted in literature the importance of CD40 as a critical 
pro-inflammatory factor in the m icroglia [132, 136], but there is contrasting 
evidence  about its presence on neuronal cells proper  [137-138].  Given the 
difficulties involved in cultivating pure populations of these cell types in vitro, 
we set up a preliminary analysis using several cell lines derived from 
transformed human neural tissue: neuroblastoma in the case of LAN-1, SH-
SY5Y, SK-N-SH, IMR-32, SK-N-BE and AF cells; neuroectodermal tumor in 
the case of LAP-35 cells. Semi-quantitative RT-PCR carried out with primers 
encompassing the entire open reading frame of CD40 revealed no detectable 
levels of CD40 transcripts in IMR-32 and AF cells, while LAN-1 displayed a 
single band about 100 bp shorter than the expected full-length amplicon (Fig. 
3.20 A). Isolation  of this aberrant band followed by  nucleotide sequence 
analysis and querying of the BLAST database ascertained it to be an aspecific 
amplicon originating from the transcript of Ribosomal Protein L3, which is 
known to have enhanced expression in many neoplastic cells [139]. Therefore, 61 
to all accounts, LAN-1 cells are CD40 transcription negative along with IMR-
32 and AF cells. All cell lines were analyzed with our assay for transcript 
variants; LAN-1, IMR-32 and AF cells were negative even with respect to 
these  partial transcripts,  while all other lines  displayed  the usual splicing 
pattern common to B cells and most other tissues. Unlike cDNA from normal 
brain, both skipping of exon 6 alone and skipping of exons 5 and 6 together 
were detected. 
 
Fig. 3.20 - Analysis of CD40 expression in cell lines derived from transformed neural tissue. A) 
Detection of CD40 
transcripts by RT-PCR and 
agarose gel electrophoresis; 
cDNA from control B -LCL 
and  vector pcDNA3-wt-
CD40 were used as positive 
controls.  B) Detection of 
CD40 protein expression 
through Western blot, probed 
with  anti-CD40 (C-20)  IgG 
(left) and reprobed with anti-
CD40 (H-120)  IgG (right); 
B-LCL lysate was used as a 
positive control. 
 
 
 
                 
 
In contrast with RT-PCR results, Western blot analysis with either anti-
CD40 (H-120) or anti-CD40 (C-20) IgG indicated that none of these cell lines 
featured detectable levels of CD40 receptor, whether they were transcription 
positive or not (Fig. 3.20 B). The number of low-molecular weigth bands 
detected by both antibodies seemed to be the outcome of aspecific binding 
rather than product degradation, since they also appeared in transcription-
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negative samples. Together, RT-PCR and Western Blot data suggest a tight 
regulation of protein expression at the post-transcriptional level. 
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4. CONCLUSIONS 
 
 
 
 
 
 
 
The task to understand the complexities of CD40 regulation is a 
challenging one. We still do not know the identity of many of its intracellular 
partners and the effects of its expression under different circumstances. The 
ability of the CD40 protein to reach cell compartments other than the plasma 
membrane prompts us  to investigate how localization affects its  function, 
whether  exposing different roles and novel interactions, or in  a merely 
regulatory way. 
Recent studies reveal that a number of proteins, expecially G protein 
coupled receptors, are expressed ‘inefficiently’ at the site normally associated 
with their biological action [140]. In some cases, large amounts of receptor 
may be destroyed without ever reaching the plasma membrane: engagement 
with the cellular quality control system regulates the delicate balance between 
either exposure on the cell surface or r etention/degradation in the ER. Our 
results suggest that functional levels of CD40 are also subjected to a similar 
control at the post-translational level. In further studies we propose to follow 
CD40 trafficking within cell vesicles and to identify its possible interactions 
with chaperone molecules, similarly to what was recently described for the 
CTLA-4 coreceptor in T cells [141]. 
The identification of several CD40 splicing variants also broadens the 
range of ways in which CD40 expression can be regulated. Even mutations in 64 
Pt.1 and Pt.3  apparently do not generate totally new non-endogenous 
transcripts, but rather impose severe limitations to the range of pre-existent 
splicing solutions. In some instances, alternative splicing may simply act as a 
restraint on gene expression by generating non productive variants, and this 
seems to be the purpose of estensive skipping of exon 2 revealed in the muscle 
tissue. In other cases, alternative isoforms could be actually translated into 
functional proteins. We gathered some evidence about the relative stability and 
surface expression  of the del5+6-CD40 variant in transfected cells; though 
were unable to isolate it from normal CD40-expressing cells by Western blot, 
flow cytometry of Pt.1 B-LCL revealed a surface antigen binding anti-CD40 
IgG which, according to RNA transcription data, probably is del5+6-CD40 
itself. The role of this transmembrane isoform has still to be defined. Since its 
extracellular domains are predictably sufficient to allow multimerization and 
pre-ligand assembly, it could be cross-linked by extracellular ligands and 
somehow modulate CD40 intracellular signalling, or simply act as a decoy. 
Through cotransfection with different constructs, in proposed investigations we 
shall also address the possibility that  del5+6-CD40  could decrease  the 
signalling  response through association with wild-type CD40 in heteromers 
marked by reduced ligand binding ability or inefficient transduction. 
Although the present work stems from B cells analysis, neuroblastoma 
cell lines also offer an easy-to-handle model to characterize post-transcriptional  
regulation  of  CD40,  since many of them  display a remarkable discrepancy 
between transcription and protein expression. Furthermore, neuroblastoma cell 
lines that lack CD40 transcripts altogether may provide a servicable negative 
model for future studies. 
Last but not least, our experimental outline pursues the synergy with the 
clinical aspects of CD40 research. Screening HIGM patients for the presence of 
additional CD40 splicing defects, a part from its intrinsic diagnostic value, 
could clarify the involvement of SR proteins in B cell specific developmental 
and functional processes. 65 
APPENDIX A 
 
ANALYSIS OF CD45 ISOFORMS VALIDATES A RAPID 
AND SENSITIVE METHOD FOR THE SCREENING OF 
TRANSCRIPT VARIANTS. 
 
 
 
 
 
 
 
 
CD45 is a transmembrane glycoprotein expressed on leukocytes [142]. 
Alternative splicing of three variable exons (4, 5 and 6 or A, B and C) allows 
the production of eight possible isoforms. In rodent cells, all of these have been 
isolated  [143-145], while in humans only five have been identified:  from 
highest to lowest molecular weight (m.w.), they are CD45R-ABC, AB, BC, B 
and 0 or  null (Fig. A.01)  [146-147]. The splicing is cell-type specific and 
activation dependent. B lymphocytes express mainly the high m.w. isoform, 
CD45RABC, while T cells express a panel of different isoforms ranging from 
the smallest one (null), found also on thymocytes, to the largest one (ABC) 
[148]. T cell activation leads to a programmed shift from high to low m.w. 
isoforms:  a complex interplay of Exonic Splicing Enhancers (ESE) and 
Silencers (ESS) enables activation-induced exon repression [ 149],  in which 
down-regulation of CD45RA expression and concomitant up-regulation of 
CD45R0 are the prominent features [150]. 66 
 
     
 
In order to validate the assay we devised for CD40 splicing variants 
analysis, we applied it to CD45 transcripts obtained from T cells selected for 
their surface expression of high or low m.w. isoforms, and eventually activated 
in vitro with Phorbol 12-Myristate 13-Acetate (PMA) and Ionomycin (Ion). 
T c ell subpopulations were  isolated from the  Ficoll-Paque  purified 
PBMC fraction of a buffy coat using MACS Separation Technology (Miltenyi) 
according to the supplier’s protocols. 
Naive CD4
+ T lymphocytes (“T-ly Naive”) were obtained via negative 
selection from PBMCs using the Naive CD4
+ T Cell Isolation Kit (Miltenyi). 
CD45RA
+ T  lymphocytes  (“T-ly RA”)  were obtained via positive 
selection from the naive T cell fraction using FITC-conjugated CD45RA 
antibodies in conjunction with the Anti-FITC  MultiSort Kit (both from 
Miltenyi). 
CD45RO
+ T  lymphocytes  (“T-ly RO”)  were obtained via positive 
selection from PBMCs using CD45RO Microbeads (Miltenyi). 
  All fractions were assayed through flow cytometry analysis with anti-
CD45RA-FITC and either anti-CD4-PE to evaluate the proportion of RA vs. 
R0 T cells, or anti-CD19-PE to detect residual B cells. Separated T-ly Naive 
and T-ly RO were rougly 20% and 10% of  total PBMCs, respectively, whereas 
T-ly RA  made up  70% of  the T -ly Naive fraction. As expected, all T cell 
fractions revealed a wide distribution of CD45 isoforms, with T-ly Naive and 
Fig. A.01 - Schematic representation 
of the alternatively spliced human 
CD45 transcripts. Of the eight 
possible combinations, only 5 were 
found in man, while all eight are 
commonly p resent in mouse cells 
[151]. CD45RABC, RAB and RBC 
are designated as the high m.w. 
isoforms, while CD45RB and R0 as 
the low m.w. isoforms. 
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T-ly RA enriched in the CD45RA surface antigen,  and T -ly RO in the 
CD45R0. No trace of B cell contamination was found. 
  Part of the T-ly Naive and T-ly RA cells were cultured for 24 h in RPMI 
medium supplemented with 10% FBS, 100 ng/ml of PMA and 1  mg/ml 
ionomycin (PMA/ion) to elicit an activation response [152]. Stimulated T cells 
were designated with the descriptor ‘PMA/ion’. 
cDNA was obtained from each fraction as described for CD40 in 
Sections 2.05. Accordingly, samples were diluted 1:20 in ddH2O and loaded on 
the ABI Prism 3730 DNA Analyzer after 30 PCR cycles with an annealing step 
at 58°C, using  1 unit of FastStart Taq DNA Polymerase (Roche) in the 
presence of 3 mM MgCl2 and 0.4mM of each PCR primer. The forward primer 
(45tr_2F: 5’-GGACACAGAAGTATTTGTGACAGG-3’), conjugated with a 
FAM dye, was designed to hybridize with exon 2, and the reverse primer 
(45tr_6R: 5’-AAAGGTGCTGGCTGTACTCCT-3’) with exon 6, thus 
spanning the whole region interested by the RA/RO alternative splicing.  In 
order to set an internal standard for relative titration of the isoforms, we 
readjusted the reaction as  a multiplex PCR by adding 0.4mM each of PCR 
primers 45tr_8F (5’-AGCTACTACTCCATCTAAGCC-3’), FAM-conjugated, 
and  45tr_9-10R (5’-ACTTTTCAACCCCTGGTG-3’). Choosing the control 
primers on exon 8 and on the exon 9-10 junction, for which no splicing was 
ever documented, provided us with an internal reference of the total presence of 
CD45 transcripts, and at the same time prevented contamination from genomic 
DNA PCR products. Moreover, using the same fluorochrome for both primer 
pairs allowed us to forego  considerations on the  comparative intensities  of 
different dyes, while still being able to distinguish the internal control amplicon 
from the splicing variants by its characteristic peak size. 
Therefore, with a single PCR we were able to detect and quantify all 
CD45 splicing variants (Fig. A.02). The identity of every PCR product was 
successfully verified through cloning and direct sequence analysis, as detailed 
in Section 2.05 for CD40 transcripts. 68 
From the qualitative point of view, GeneMapper plots revealed a 2-6 nt 
discrepancy between the expected and observed size of each peak (Table A.01). 
According to the software documentation, such variations are within the normal 
running parameters of GeneMapper and depend on fluorochrome conjugates, 
Taq DNA polymerase efficiency and amplicon length. Since these size 
variations were constant for each peak in the course of repeated experiments, 
this bias did not ultimately affect the precision of our assay, and each peak 
could be unambiguously assigned to a specific CD45 splicing variant. 
 
 
 
 
In T -ly R0 only the peaks corresponding to the low m.w. isoforms 
(CD45R0 and RB) were detected. The intensity of CD45R0 appears greater 
than the internal control because its shorter size entails greater PCR efficiency. 
Similarly, though we found all isoforms in T -ly Naïve and T -ly RA as 
expected, the peaks corresponding to CD45R0/RB were higher than those of 
the heavier isoforms: again, this is due to amplification efficiency. In fact, by 
performing the PCR with the less processive AmpliTaq Gold DNA polymerase 
Fig. A.02 - GeneMapper plot of the CD45 transcripts from the different T cell fractions. 
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(Applied Biosystems), we observed the profile of the peaks change according 
to their size: low m.w. isoforms appeared even higher and high m.w. even 
lower, in an almost linear fashion (data not shown). This implies that direct 
comparison of the peak intensities within each sample  is not a l egitimate 
method to calculate the RA/R0 ratio, as the  absolute quantity of the RA 
isoforms will be displayed as being lower than R0 isoforms due to PCR 
efficiency, though very likely the reverse is true. We c ould  instead track 
changes in the relative levels of each isoform among different samples, e.g. 
stimulated vs. resting. We normalized the intensity of the control peaks across 
all samples and calculated the heights of the splicing variant-associated peaks 
in each sample as a percentage ratio of the control amplicon (Table A.01). 
 
Table A.01  Peak Size (nt)  Normalized Peak Heights (%) 
Included 
Exons  Expected  Observed  T-Ly 
Naive 
T-Ly 
Naive + 
PMA/ion 
T-Ly RA 
T-Ly RA 
+ 
PMA/ion 
T-Ly R0 
Ctrl  260  258  100%  100%  100%  100%  100% 
CD45RABC  562  559  6,2  2,6  9,7  4,2  0 
CD45RAB  418  412  9,6  4,7  11,7  6,0  3,4 
CD45RBC  364  358  5,3  10,1  6,5  11,5  2,5 
CD45RB  220  214  17,7  34,5  12,2  29,4  66,1 
CD45R0  79  74  18,4  32,0  5,4  13,5  183,1 
 
  According to this relative quantification method, 24 h stimulation with 
PMA + ion led to a marked increase in the low m.w. CD45R0 and RB isoforms 
and a concomitant decrease in the CD45RA isoforms (ABC, AB) for both T-ly 
Naive and T-ly RA cells (Fig. A.03). We could also describe a rise in the levels 
of CD45RBC: it may reflect a tendency of activated T cells to preferentially 
skip CD45 exon 4 rather than exon 6 when they begin to shift their splicing 
pattern toward low m.w. isoforms, as reported by various investigators [153-
154]. 
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As expected, non-stimulated  T-ly  RA  cells  were enriched in RA 
isoforms compared to T-ly Naive cells (Fig. A.04), while the T-ly R0 fraction 
had practically no high m.w. CD45 isoforms compared to all other fractions 
(Fig. A.05). 
Fig.  A.03  - Comparison between the relative expression levels of CD45 splicing isoforms in 
stimulated and resting Naive CD4
+ T cells (A) and CD45RA
+ T cells (B). 
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  Observations based on these relative measurements agree with the 
variations in CD45 isoforms expression described in literature [149, 151, 153, 
154], effectively validating our transcript analysis method even with respect to 
quantitative considerations. 
Fig. A.05 - Relative expression levels of CD45 splicing isoforms in resting CD45R0
+
 T cells. 
Fig. A.04 - Comparison between the relative expression levels of CD45 splicing isoforms in resting 
Naive CD4
+ T cells and CD45RA
+ T cells. 
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